<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">77415</article-id><article-id pub-id-type="doi">10.7554/eLife.77415</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Structural Biology and Molecular Biophysics</subject></subj-group></article-categories><title-group><article-title>Dilated cardiomyopathy mutation E525K in human beta-cardiac myosin stabilizes the interacting-heads motif and super-relaxed state of myosin</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-270667"><name><surname>Rasicci</surname><given-names>David V</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-270665"><name><surname>Tiwari</surname><given-names>Prince</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-289854"><name><surname>Bodt</surname><given-names>Skylar ML</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-270668"><name><surname>Desetty</surname><given-names>Rohini</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-270666"><name><surname>Sadler</surname><given-names>Fredrik R</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-48156"><name><surname>Sivaramakrishnan</surname><given-names>Sivaraj</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9541-6994</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-50258"><name><surname>Craig</surname><given-names>Roger</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9707-5409</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-211464"><name><surname>Yengo</surname><given-names>Christopher M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3987-9019</contrib-id><email>cmy11@psu.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02c4ez492</institution-id><institution>Department of Cellular and Molecular Physiology, Penn State College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Hershey</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0464eyp60</institution-id><institution>Department of Radiology, Division of Cell Biology and Imaging, UMass Chan Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Worcester</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/017zqws13</institution-id><institution>Department of Genetics, Cell Biology, and Development, University of Minnesota Twin Cities</institution></institution-wrap><addr-line><named-content content-type="city">Minneapolis</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Sellers</surname><given-names>James R</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>National Heart, Lung and Blood Institute, National Institutes of Health</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Akhmanova</surname><given-names>Anna</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04pp8hn57</institution-id><institution>Utrecht University</institution></institution-wrap><country>Netherlands</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>24</day><month>11</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e77415</elocation-id><history><date date-type="received" iso-8601-date="2022-01-28"><day>28</day><month>01</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-11-08"><day>08</day><month>11</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-02-19"><day>19</day><month>02</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.02.18.480995"/></event></pub-history><permissions><copyright-statement>© 2022, Rasicci et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Rasicci et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-77415-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-77415-figures-v1.pdf"/><abstract><p>The auto-inhibited, super-relaxed (SRX) state of cardiac myosin is thought to be crucial for regulating contraction, relaxation, and energy conservation in the heart. We used single ATP turnover experiments to demonstrate that a dilated cardiomyopathy (DCM) mutation (E525K) in human beta-cardiac myosin increases the fraction of myosin heads in the SRX state (with slow ATP turnover), especially in physiological ionic strength conditions. We also utilized FRET between a C-terminal GFP tag on the myosin tail and Cy3ATP bound to the active site of the motor domain to estimate the fraction of heads in the closed, interacting-heads motif (IHM); we found a strong correlation between the IHM and SRX state. Negative stain electron microscopy and 2D class averaging of the construct demonstrated that the E525K mutation increased the fraction of molecules adopting the IHM. Overall, our results demonstrate that the E525K DCM mutation may reduce muscle force and power by stabilizing the auto-inhibited SRX state. Our studies also provide direct evidence for a correlation between the SRX biochemical state and the IHM structural state in cardiac muscle myosin. Furthermore, the E525 residue may be implicated in crucial electrostatic interactions that modulate this conserved, auto-inhibited conformation of myosin.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cardiac muscle myosin</kwd><kwd>FRET</kwd><kwd>super-relaxed state</kwd><kwd>interacting-heads motif</kwd><kwd>dilated cardiomyopathy</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>None</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL127699</award-id><principal-award-recipient><name><surname>Yengo</surname><given-names>Christopher M</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL150953</award-id><principal-award-recipient><name><surname>Yengo</surname><given-names>Christopher M</given-names></name><name><surname>Sivaramakrishnan</surname><given-names>Sivaraj</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AR072036</award-id><principal-award-recipient><name><surname>Craig</surname><given-names>Roger</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL139883</award-id><principal-award-recipient><name><surname>Craig</surname><given-names>Roger</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HL164560</award-id><principal-award-recipient><name><surname>Craig</surname><given-names>Roger</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>916818</award-id><principal-award-recipient><name><surname>Tiwari</surname><given-names>Prince</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A dilated cardiomyopathy mutation can stabilize the auto-inhibited super-relaxed state and interacting-heads motif in human cardiac myosin, suggesting a mechanism by which disease mutations can reduce muscle force and power.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Muscle contraction is driven by the sliding of thick and thin filaments in the muscle sarcomere. In striated muscle, contraction is regulated by both thin and thick filament mechanisms. It is well established that a rise in intracellular calcium concentration changes the conformation of the actin-containing thin filaments (thin filament regulation), allowing myosin heads in the thick filament to bind to actin and power filament sliding (<xref ref-type="bibr" rid="bib28">Kobayashi and Solaro, 2005</xref>). Recently, thick filament regulation has garnered much attention, as myosin heads can form an auto-inhibited or super-relaxed (SRX) state with slow ATP turnover (<xref ref-type="bibr" rid="bib25">Hooijman et al., 2011</xref>; <xref ref-type="bibr" rid="bib38">Nag and Trivedi, 2021</xref>; <xref ref-type="bibr" rid="bib52">Stewart et al., 2010</xref>). Structural studies have shown that myosin heads in the thick filament can fold back on the myosin tail and interact with each other in a conformation referred to as the interacting-heads motif (IHM; <xref ref-type="bibr" rid="bib6">Alamo et al., 2018</xref>; <xref ref-type="bibr" rid="bib71">Woodhead et al., 2005</xref>; <xref ref-type="bibr" rid="bib79">Zoghbi et al., 2008</xref>), which prevents them from interacting with actin. However, it is currently unclear if the SRX biochemical state and IHM structural state are directly correlated (<xref ref-type="bibr" rid="bib16">Craig and Padrón, 2022</xref>).</p><p>The SRX state is proposed to play several important roles in cardiac muscle. It appears to play a crucial role in conserving energy, as SRX heads turn over ATP about 5–10 times slower than the uninhibited disordered relaxed (DRX) heads (<xref ref-type="bibr" rid="bib25">Hooijman et al., 2011</xref>; <xref ref-type="bibr" rid="bib55">Toepfer et al., 2020</xref>). Cardiac muscle may also use the SRX heads as a reserve that can be recruited when peripheral metabolic demands warrant-increased cardiac contractility (<xref ref-type="bibr" rid="bib36">McNamara et al., 2015</xref>). It has been hypothesized that regulation of the SRX state in cardiac muscle underlies the Frank-Starling mechanism, in which contractile force increases as cardiac muscle is stretched (i.e. length-dependent activation; <xref ref-type="bibr" rid="bib10">Campbell et al., 2018</xref>; <xref ref-type="bibr" rid="bib27">Kampourakis and Irving, 2021</xref>; <xref ref-type="bibr" rid="bib77">Zhang et al., 2017</xref>).</p><p>Point mutations in cardiac myosin can lead to various forms of cardiomyopathy, with hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) being the most common phenotypes (<xref ref-type="bibr" rid="bib75">Yotti et al., 2019</xref>). HCM most commonly presents clinically as hypertrophy of the interventricular septum, while other forms of hypertrophy are also found including concentric, midventricular, and apical. The hypertrophy results in decreased left ventricular chamber size and is accompanied by pronounced relaxation deficits, myofilament disarray, and fibrosis. Preclinical individuals have been found to display increased ejection fraction and impaired relaxation suggesting a hypercontractile phenotype occurs prior to hypertrophy (<xref ref-type="bibr" rid="bib24">Ho et al., 2002</xref>; <xref ref-type="bibr" rid="bib39">Nagueh et al., 2003</xref>). Recent work has revealed that several HCM mutations in cardiac myosin can destabilize the SRX state (<xref ref-type="bibr" rid="bib2">Adhikari et al., 2019</xref>; <xref ref-type="bibr" rid="bib8">Anderson et al., 2018</xref>; <xref ref-type="bibr" rid="bib21">Gollapudi et al., 2021</xref>; <xref ref-type="bibr" rid="bib46">Sarkar et al., 2020</xref>; <xref ref-type="bibr" rid="bib64">Vander Roest et al., 2021</xref>), which may explain the impaired relaxation and hypercontractile phenotype. On the other hand, DCM presents as an increase in left ventricular chamber size which leads to thinning of the myocardium, cardiomyocyte cell death, and a hypocontractile phenotype (<xref ref-type="bibr" rid="bib35">McNally and Mestroni, 2017</xref>). Interestingly, early-stage DCM patients present with subtle decreases in contractility and ejection fraction, suggesting hypocontractility may trigger disease onset (<xref ref-type="bibr" rid="bib31">Lakdawala et al., 2012b</xref>; <xref ref-type="bibr" rid="bib48">Schafer et al., 2017</xref>). An attractive hypothesis is that DCM mutations may stabilize the SRX state, which reduces the number of myosin heads available to produce contractile force and could explain the observed hypocontractility. However, the leading hypothesis is that DCM mutations reduce the intrinsic motor properties of myosin without altering the SRX state (<xref ref-type="bibr" rid="bib44">Robert-Paganin et al., 2018</xref>; <xref ref-type="bibr" rid="bib62">Ujfalusi et al., 2018</xref>), although few studies have examined the impact of DCM mutations on the SRX state (<xref ref-type="bibr" rid="bib76">Yuan et al., 2022</xref>).</p><p>The IHM, which appears to be a conserved regulatory structure in all muscle types (<xref ref-type="bibr" rid="bib6">Alamo et al., 2018</xref>; <xref ref-type="bibr" rid="bib33">Lee et al., 2018</xref>), has been proposed to be the structural basis of the SRX state (<xref ref-type="bibr" rid="bib16">Craig and Padrón, 2022</xref>). The motif is found in both single myosin molecules and native thick filaments. Early studies with smooth and non-muscle myosin revealed a folded tail conformation that was proposed to be auto-inhibitory (<xref ref-type="bibr" rid="bib15">Craig et al., 1983</xref>; <xref ref-type="bibr" rid="bib40">Onishi and Wakabayashi, 1982</xref>; <xref ref-type="bibr" rid="bib58">Trybus et al., 1982</xref>; <xref ref-type="bibr" rid="bib59">Trybus and Lowey, 1984</xref>). A study with smooth muscle myosin was the first to reveal the interactions between the heads that characterize the IHM (<xref ref-type="bibr" rid="bib68">Wendt et al., 1999</xref>; <xref ref-type="bibr" rid="bib69">Wendt et al., 2001</xref>) and later how the folded tail stabilizes the interacting heads (<xref ref-type="bibr" rid="bib9">Burgess et al., 2007</xref>). The motif subsequently has been demonstrated in myosin II molecules across the evolutionary tree, from humans to the earliest animals (e.g. sponges; <xref ref-type="bibr" rid="bib26">Jung et al., 2008</xref>; <xref ref-type="bibr" rid="bib33">Lee et al., 2018</xref>). Further biochemical studies demonstrated that the IHM is the auto-inhibited structure that predominates in the dephosphorylated off-state (<xref ref-type="bibr" rid="bib9">Burgess et al., 2007</xref>; <xref ref-type="bibr" rid="bib17">Cross et al., 1988</xref>; <xref ref-type="bibr" rid="bib69">Wendt et al., 2001</xref>). Three recent cryo-EM studies of smooth muscle myosin solved the high-resolution structure of the IHM, providing crucial details about head-head and head-tail interactions that stabilize the structure (<xref ref-type="bibr" rid="bib23">Heissler et al., 2021</xref>; <xref ref-type="bibr" rid="bib47">Scarff et al., 2020</xref>; <xref ref-type="bibr" rid="bib74">Yang et al., 2020</xref>). The IHM was first demonstrated in native thick filaments in tarantula muscle (<xref ref-type="bibr" rid="bib71">Woodhead et al., 2005</xref>) and then was shown to be conserved in thick filaments throughout the animal kingdom, including vertebrates (<xref ref-type="bibr" rid="bib7">AlKhayat et al., 2013</xref>; <xref ref-type="bibr" rid="bib5">Alamo et al., 2017</xref>; <xref ref-type="bibr" rid="bib79">Zoghbi et al., 2008</xref>). The highest resolution so far (13 Å) has come from tarantula filaments (<xref ref-type="bibr" rid="bib73">Yang et al., 2016</xref>), which showed an IHM with similar features to smooth muscle myosin (<xref ref-type="bibr" rid="bib6">Alamo et al., 2018</xref>; <xref ref-type="bibr" rid="bib4">Alamo et al., 2008</xref>). However, in skeletal and cardiac myosin, the high-resolution structure of the IHM has not been solved.</p><p>In order to directly examine the correlation between the IHM and SRX state, a method that can detect the IHM in solution in addition to the fraction of molecules with slow ATP turnover is crucial. In the current study, we developed a method of detecting the IHM in solution by FRET, allowing us to directly correlate the fraction of myosin heads in the IHM with the fraction of myosin heads in the slow ATP turnover (SRX) state. In addition, we examined the impact of a DCM-associated mutation, E525K, on the formation of the IHM structural and SRX biochemical states. We found that the E525K mutation dramatically stabilizes the SRX state, monitored by single ATP turnover, as well as the IHM, monitored by FRET and confirmed by single molecule EM imaging. Our results suggest that stabilization of the off-state is a viable explanation for the decrease in muscle force and power in DCM. We also demonstrate that the IHM correlates well with the SRX state, providing evidence that the IHM is the structural basis of the SRX biochemical state.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Overall approach and rationale</title><p>Our initial goal was to produce a human beta-cardiac myosin construct that would allow us to monitor formation of the SRX biochemical and IHM structural states in solution. Previous studies in smooth muscle myosin demonstrated that at least 15 heptads of the S2 region of myosin were required for phosphorylation-dependent regulation (<xref ref-type="bibr" rid="bib60">Trybus et al., 1997</xref>). Thus, we generated human beta-cardiac heavy meromyosin (HMM) with 15 heptads of S2, a leucine zipper, and a C-terminal GFP tag (M2β 15HPZ.GFP; <xref ref-type="fig" rid="fig1">Figure 1</xref>). We expressed and purified M2β 15HPZ.GFP using the C2C12 expression system (<xref ref-type="bibr" rid="bib11">Chow et al., 2002</xref>; <xref ref-type="bibr" rid="bib67">Wang et al., 2003</xref>), and the myosin contained endogenous mouse skeletal muscle light chains. This is similar in composition to our published studies on S1 (<xref ref-type="bibr" rid="bib43">Rasicci et al., 2021</xref>; <xref ref-type="bibr" rid="bib53">Swenson et al., 2017</xref>; <xref ref-type="bibr" rid="bib54">Tang et al., 2021</xref>). We reasoned that if M2β 15HPZ.GFP forms the IHM then we should be able to observe FRET between Cy3ATP bound to the active site and the C-terminal GFP tag, thus essentially functioning as a biosensor of the IHM or closed state. We generated a model of the open and closed states of M2β 15HPZ.GFP and found that the predicted distance between the active site of the free head (FH) and its C-terminal GFP tag is about 90–140 Å, assuming the GFP tags are flexibly linked to the tail, which is close enough to participate in FRET. All other donor-acceptor pairs (blocked head [BH] to either C-terminal GFP tag, FH to the BH C-terminal GFP) have distances ~130–140 Å (<xref ref-type="fig" rid="fig1">Figure 1</xref>). In contrast, the distance in the open state is predicted to be ≥250 Å, which is much too far to participate in FRET. Therefore, we proposed that the FRET biosensor would be able to detect the IHM formation in solution and that the FRET distance observed would be an ensemble average of all donor acceptor pairs, which are in the range of 90–140 Å apart in the IHM.</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Molecular models of the M2β 15HPZ.GFP construct in open and closed (interacting-heads motif [IHM]) states.</title><p>From proximal to distal, the model contains myosin heavy chains (orange and cyan), each with one essential light chain (white) and one regulatory light chain (yellow). Following the last residue of the 15 heptad tail (E946), the leucine zipper (PDB: 1ZIL, gray) helps to dimerize the construct and is followed by a short, flexible glycine linker (pink), and then the C-terminal GFP molecule (PDB: 1GFL, green). Distances in the figure are measured from Y66 within the tripeptide fluorophore of GFP to S180 in the ATP-binding site of the myosin motor domain. Models were constructed by joining existing pdb files in UCSF Chimera software. The open state is based on a previously published model by the Spudich lab (<xref ref-type="bibr" rid="bib56">Trivedi et al., 2018</xref>), while the closed state is based on the 5TBY cardiac homology model from the Padrón lab (<xref ref-type="bibr" rid="bib5">Alamo et al., 2017</xref>). In the closed state, the free head (FH) of myosin lies closer to the C-terminal GFP molecules, as compared to the blocked head (BH).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77415-fig1-v1.tif"/></fig></sec><sec id="s2-2"><title>Actin-activated ATPase and in vitro motility</title><p>The WT and E525K M2β 15HPZ.GFP preparations were &gt;95% pure based on SDS-PAGE and similar in purity to our M2β S1 preparations (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). To examine the number of active heads in the M2β S1 and 15HPZ.GFP preparations, we performed high-salt NH<sub>4</sub><sup>+</sup> ATPase assays in the absence of actin (<xref ref-type="bibr" rid="bib61">Trybus, 2000</xref>). The ATPase activity per head was similar when comparing WT S1 to WT 15HPZ.GFP (4.24±0.09 and 4.14±0.08 s<sup>–1</sup>, respectively) and E525K S1 to E525K 15HPZ.GFP (5.03±0.09 and 4.93±0.03 s<sup>–1</sup>, respectively). However, E525K displayed a 20% higher NH<sub>4</sub><sup>+</sup> ATPase rate in both the S1 and 15HPZ.GFP preparations. Our NH<sub>4</sub><sup>+</sup> ATPase and SDS-PAGE results demonstrate that the M2β 15HPZ.GFP construct does not disrupt the folding of the myosin motor domain.</p><p>In order to examine the ability of M2β 15HPZ.GFP to form the SRX state, we first examined steady-state ATPase activity in the presence of varying concentrations of actin (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). We predicted that the ATPase activity would be decreased compared to our previous studies with monomeric S1, if the HMM construct could form the SRX state. The maximum actin-activated ATPase activity (<italic>k</italic><sub>cat</sub>) of WT M2β 15HPZ.GFP was reduced sevenfold compared to our measurements with WT M2β S1 (<xref ref-type="bibr" rid="bib54">Tang et al., 2021</xref>), while the actin concentration at which the ATPase activity is one-half maximal (<italic>K</italic><sub>ATPase</sub>) was not significantly different in low-salt conditions (20 mM KCl; <xref ref-type="table" rid="table1">Table 1</xref>). In the WT and E525K M2β 15HPZ.GFP constructs, the <italic>k</italic><sub>cat</sub> and <italic>K</italic><sub>ATPase</sub> were not significantly different.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Steady-state actin-activated ATPase activity and in vitro motility.</title><p>(<bold>A</bold>) The ATPase activity of WT and E525K M2β 15HPZ.GFP (heavy meromyosin [HMM]) was measured as a function of actin concentration, and the data were fit to a hyperbolic function to determine <italic>k</italic><sub>cat</sub> and <italic>K</italic><sub>ATPase</sub>. (<bold>B</bold>) The ATPase activity of WT and E525K M2β S1 (S1) was also measured as in panel A. (<bold>C</bold>) In vitro motility assays were used to examine actin gliding velocities of HMM constructs. The individual data points are plotted for three protein preparations, shown in three different colors (yellow, blue, and red), and the average for each preparation is represented by the colored triangles. The overall average velocity is represented by the black line. Measurements are from at least three protein preparations (± SD). See <xref ref-type="table" rid="table1">Table 1</xref> for summary of values and statistical comparisons.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Excel files with data from <xref ref-type="fig" rid="fig2">Figure 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77415-fig2-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77415-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>SDS-gel of M2β S1 and 15HPZ.</title><p>GFP preparations. Purified myosin was run on a 4–15% SDS-gel at a concentration of 1 µM (2.76 µg for M2β-S1 and 3.62 µg for M2β 15HPZ.GFP). The higher molecular weight bands are the human recombinant myosin heavy chains (predicted Mw of M2β S1=99,022 Da and M2β 15HPZ.GFP=140,674 Da), and the lower molecular weight bands are the mixture of endogenous mouse myosin light chains (between 15 and 25 kDa) that co-purify with M2β. We identified the myosin light chains in the S1 prep by mass spectrometry in a previous publication (<xref ref-type="bibr" rid="bib53">Swenson et al., 2017</xref>).</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Uncropped SDS-PAGE of WT and E525K S1 and 15HPZ.GFP.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77415-fig2-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77415-fig2-figsupp1-v1.tif"/></fig><media mimetype="video" mime-subtype="mp4" xlink:href="elife-77415-fig2-video1.mp4" id="fig2video1"><label>Figure 2—video 1.</label><caption><title>In vitro motility assay.</title><p>Representative movies of actin gliding generated by WT and E525K M2β 15HPZ.GFP. Myosin was directly attached to the nitrocellulose motility surface and Alexa-555 labeled actin was visualized by time lapsed microscopy (1 frame per second for 2 min). Images were exported to ImageJ to generate videos.</p></caption></media></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Summary of steady-state ATPase and in vitro motility measurements (± SE).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Parameter</th><th align="center" valign="middle">WTM2β 15HPZ.GFP (N=3–5)</th><th align="center" valign="middle">E525KM2β 15HPZ.GFP (N=3)</th><th align="center" valign="middle">WTM2β S1(N=3–6)</th><th align="center" valign="middle">E525KM2β S1(N=3)</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>v</italic><sub>0</sub> (s<sup>–1</sup>)</td><td align="center" valign="middle">0.02±0.01, N=5</td><td align="center" valign="middle">0.01±0.01</td><td align="center" valign="middle">0.02±0.01, N=6</td><td align="center" valign="middle">0.03±0.01</td></tr><tr><td align="left" valign="bottom"><italic>k</italic><sub>cat</sub> (s<sup>–1</sup>)</td><td align="center" valign="middle">1.1±0.49, N=5</td><td align="center" valign="middle">0.41±0.09</td><td align="center" valign="middle"><sup><xref ref-type="table-fn" rid="table1fn1">*</xref></sup>7.8±0.7, N=6</td><td align="center" valign="middle"><sup><xref ref-type="table-fn" rid="table1fn2">†</xref></sup>10.6±0.3</td></tr><tr><td align="left" valign="bottom"><italic>K</italic><sub>ATPase</sub> (µM)</td><td align="center" valign="middle">99.9±64.5, N=5</td><td align="center" valign="middle">53.3±20.8</td><td align="center" valign="middle">52.2±8.6, N=6</td><td align="center" valign="middle"><sup><xref ref-type="table-fn" rid="table1fn2">†</xref></sup>1.8±0.4</td></tr><tr><td align="left" valign="bottom">Average sliding velocity (nm/s)</td><td align="center" valign="middle">853±54, N=3</td><td align="center" valign="middle">852±58</td><td align="center" valign="middle"><sup><xref ref-type="table-fn" rid="table1fn1">*</xref>, <xref ref-type="table-fn" rid="table1fn3">‡</xref></sup>1591±16, N=3</td><td align="center" valign="middle">N.D.</td></tr><tr><td align="left" valign="bottom">Percent stuck filaments</td><td align="center" valign="middle">27.8±9.5, N=3</td><td align="center" valign="middle">34.8±5.4</td><td align="center" valign="middle">≤5, N=3</td><td align="center" valign="middle">N.D.</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><label>*</label><p>p&lt;0.005 comparing WT M2β S1 to WT M2β 15HPZ.GFP.</p></fn><fn id="table1fn2"><label>†</label><p>p&lt;0.05 comparing E525K M2β S1 to WT M2β S1 (unpaired Student’s t-test).</p></fn><fn id="table1fn3"><label>‡</label><p>Data is from <xref ref-type="bibr" rid="bib54">Tang et al., 2021</xref>.</p></fn></table-wrap-foot></table-wrap><p>In order to determine if the E525K mutation alters the intrinsic ATPase activity, in the absence of regulation by the IHM formation, we examined actin-activated ATPase activity in the WT and E525K M2β S1 constructs in parallel (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="table" rid="table1">Table 1</xref>). To our surprise, we found that the mutation increases <italic>k</italic><sub>cat</sub> 20% and dramatically reduces the <italic>K</italic><sub>ATPase</sub> 30-fold. Thus, the E525K mutation enhances catalytic efficiency in S1, but the SRX state is still able to suppress actin-activated ATPase activity in the double-headed HMM construct.</p><p>We also performed in vitro gliding assays and found that the average in vitro gliding velocity was similar in WT and E525K M2β 15HPZ.GFP (<xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="video" rid="fig2video1">Figure 2—video 1</xref>). The velocities were similar to previous reports with a longer HMM construct (<xref ref-type="bibr" rid="bib70">Winkelmann et al., 2015</xref>) but slower than our published results with S1 (<xref ref-type="bibr" rid="bib54">Tang et al., 2021</xref>). There was a larger number of stuck filaments in our HMM experiments compared to S1 (<xref ref-type="table" rid="table1">Table 1</xref>), suggesting that myosin in the auto-inhibited SRX state may adopt a conformation on the motility surface that can bind actin and generate a drag force that opposes the filament sliding.</p></sec><sec id="s2-3"><title>Single mantATP turnover experiments</title><p>We used mant-labeled ATP (mant labeled at the 3’ ribose position) to monitor single turnover rate constants in the absence of actin (<xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="table" rid="table2">Table 2</xref>). Previous studies have demonstrated that cardiac myosin exhibits two phases in single turnover measurements, a fast phase that is similar to the basal ATPase rate of S1 and a slow phase that is 5–10-fold slower and referred to as the SRX state (<xref ref-type="bibr" rid="bib8">Anderson et al., 2018</xref>; <xref ref-type="bibr" rid="bib25">Hooijman et al., 2011</xref>; <xref ref-type="bibr" rid="bib45">Rohde et al., 2018</xref>). Determining the relative amplitudes of the fast and slow phase rate constants allows determination of the fraction of myosin molecules in the open (DRX) and SRX states, respectively. We performed single turnover measurements at various KCl concentrations and observed that KCl destabilizes the SRX state in WT M2β 15HPZ.GFP, becoming a minor component at 150 mM KCl (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, C–figure supplement 1). However, E525K exhibited a much higher fraction of molecules in the SRX state compared to WT, especially at higher KCl concentrations (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, C-figure supplement 2). Thus, our results demonstrate E525K stabilizes the SRX state even under physiological ionic strength conditions. The observed rate constants for the fast and slow components of the transients were relatively similar (~within twofold) in WT and E525K M2β 15HPZ.GFP (<xref ref-type="fig" rid="fig3">Figure 3D</xref> and <xref ref-type="table" rid="table2">Table 2</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Single ATP turnover measurements.</title><p>The turnover of mantATP by M2β 15HPZ.GFP was examined at varying KCl concentrations. The fluorescence transients from (<bold>A</bold>) WT or (<bold>B</bold>) E525K M2β 15HPZ.GFP (0.25 µM) that was pre-incubated with mantATP (1 µM) for ~30 s and then mixed with saturating unlabeled ATP (2 mM) were observed for 1000 s. The mant fluorescence transients were best fit to a two-exponential function. (<bold>C</bold>) The relative amplitude of the slow rate constants from the fluorescence transients was used to determine the fraction of heads in the super-relaxed (SRX) state. The mutant had a significantly greater SRX state fraction than WT at all KCl concentrations. (<bold>D</bold>) The slow-rate constants (SRX state) were 5–10 times slower than the fast-rate constants (disordered relaxed [DRX] state), and relatively similar (~within twofold) at each KCl concentration for both the WT and E525K constructs. Error bars are ± SD, N=3 separate protein preparations with one technical replicate per prep (*p&lt;0.005, comparing WT and E525K, unpaired Student’s t-test). See <xref ref-type="table" rid="table2">Table 2</xref> for summary of values.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Excel files with data from <xref ref-type="fig" rid="fig3">Figure 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77415-fig3-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77415-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Single turnover with WT M2β 15HPZ.</title><p>GFP. Representative data from single mantATP turnover measurements that are presented in <xref ref-type="fig" rid="fig3">Figure 3A</xref> of the main text. The fluorescence transients and the fit of the transients to a two-exponential function at 20, 50, 75, 100, and 150 mM KCl are shown for WT M2β 15HPZ.GFP in panels <bold>A</bold>, <bold>B</bold>, <bold>C</bold>, <bold>D</bold>, and <bold>E</bold>, respectively. The residuals are shown above each plot.</p><p><supplementary-material id="fig3s1sdata1"><label>Figure 3—figure supplement 1—source data 1.</label><caption><title>Excel files with data from <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77415-fig3-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77415-fig3-figsupp1-v1.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Single turnover with E525K M2β 15HPZ.</title><p>GFP. Representative data from single mantATP turnover measurements that are presented in <xref ref-type="fig" rid="fig3">Figure 3B</xref> of the main text. The fluorescence transients and the fit of the transients to a two-exponential function at 20, 50, 75, 100, and 150 mM KCl are shown for E525K M2β 15HPZ.GFP in panels <bold>A</bold>, <bold>B</bold>, <bold>C</bold>, <bold>D</bold>, and <bold>E</bold>, respectively. The residuals are shown above each plot.</p><p><supplementary-material id="fig3s2sdata1"><label>Figure 3—figure supplement 2—source data 1.</label><caption><title>Excel files with data from <xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77415-fig3-figsupp2-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77415-fig3-figsupp2-v1.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Single ATP turnover measurements with M2β S1.</title><p>The turnover of mantATP by M2β S1 WT (<bold>A</bold>) or E525K (<bold>B</bold>) was examined at varying KCl concentrations as in <xref ref-type="fig" rid="fig3">Figure 3</xref>. The mant fluorescence transients were best fit to a three-exponential function. There was a minor very fast phase (~5% of the signal), which can be attributed to a small amount of mantADP release from S1 (2–4 s<sup>–1</sup>) and therefore was not included in the analysis of the other two rate constants. (<bold>C</bold>) The relative amplitude of the slow-rate constant was used to determine the fraction of heads in the super-relaxed (SRX) state. (<bold>D</bold>) The slow rate constant (SRX state) was mostly similar in WT S1 and E525K S1 while the predominant rate constant (disordered relaxed [DRX] state), which dominated the fluorescence transients (90–95% of the signal), was significantly higher in E525K compared to WT. (<bold>E</bold>) The DRX state rate constants were faster in WT S1 compared to WT heavy meromyosin (HMM), while the SRX state rate constant was similar. (<bold>F</bold>) Both the DRX and the SRX rate constants were significantly faster in E525K S1 compared to E525K HMM. All rate constants were relatively insensitive to KCl concentration (see <xref ref-type="table" rid="table2 table3">Tables 2 and 3</xref> for summary of values; *p&lt;0.005, unpaired Student’s t-test).</p><p><supplementary-material id="fig3s3sdata1"><label>Figure 3—figure supplement 3—source data 1.</label><caption><title>Excel files with data from <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77415-fig3-figsupp3-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77415-fig3-figsupp3-v1.tif"/></fig></fig-group><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Summary of single mantATP turnover measurements for WT and E525K M2β 15HPZ.GFP (N=3,± SD).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Conditions</th><th align="center" valign="bottom">Disordered relaxed (DRX) rate</th><th align="center" valign="bottom">DRX fraction</th><th align="center" valign="bottom">Super-relaxed (SRX) rate</th><th align="center" valign="bottom">SRX fraction</th></tr><tr><th align="left" valign="bottom" colspan="5">WT</th></tr></thead><tbody><tr><td align="char" char="." valign="bottom">20 mM KCl</td><td align="center" valign="bottom">0.014±0.002</td><td align="center" valign="bottom">0.11±0.01</td><td align="center" valign="bottom">0.0033±0.0001</td><td align="center" valign="bottom">0.89±0.01</td></tr><tr><td align="char" char="." valign="bottom">50 mM KCl</td><td align="center" valign="bottom">0.013±0.001</td><td align="center" valign="bottom">0.43±0.05</td><td align="center" valign="bottom">0.0054±0.0005</td><td align="center" valign="bottom">0.57±0.05</td></tr><tr><td align="char" char="." valign="bottom">75 mM KCl</td><td align="center" valign="bottom">0.015±0.002</td><td align="center" valign="bottom">0.59±0.08</td><td align="center" valign="bottom">0.0069±0.0009</td><td align="center" valign="bottom">0.41±0.08</td></tr><tr><td align="char" char="." valign="bottom">100 mM KCl</td><td align="center" valign="bottom">0.016±0.001</td><td align="center" valign="bottom">0.85±0.03</td><td align="center" valign="bottom">0.0058±0.0004</td><td align="center" valign="bottom">0.15±0.03</td></tr><tr><td align="char" char="." valign="bottom">150 mM KCl</td><td align="center" valign="bottom">0.018±0.001</td><td align="center" valign="bottom">0.87±0.02</td><td align="center" valign="bottom">0.0071±0.0008</td><td align="center" valign="bottom">0.13±0.02</td></tr><tr><th align="left" valign="bottom" colspan="5">E525K</th></tr><tr><td align="char" char="." valign="bottom">20 mM KCl</td><td align="center" valign="bottom">0.027±0.008</td><td align="center" valign="bottom">0.05±0.01</td><td align="center" valign="bottom">0.0022±0.0002</td><td align="center" valign="bottom">0.95±0.01</td></tr><tr><td align="char" char="." valign="bottom">50 mM KCl</td><td align="center" valign="bottom">0.019±0.002</td><td align="center" valign="bottom">0.06±0.01</td><td align="center" valign="bottom">0.0026±0.0001</td><td align="center" valign="bottom">0.94±0.01</td></tr><tr><td align="char" char="." valign="bottom">75 mM KCl</td><td align="center" valign="bottom">0.016±0.006</td><td align="center" valign="bottom">0.08±0.02</td><td align="center" valign="bottom">0.0030±0.0001</td><td align="center" valign="bottom">0.92±0.02</td></tr><tr><td align="char" char="." valign="bottom">100 mM KCl</td><td align="center" valign="bottom">0.014±0.003</td><td align="center" valign="bottom">0.10±0.02</td><td align="center" valign="bottom">0.0033±0.0001</td><td align="center" valign="bottom">0.90±0.02</td></tr><tr><td align="char" char="." valign="bottom">150 mM KCl</td><td align="center" valign="bottom">0.013±0.002</td><td align="center" valign="bottom">0.21±0.03</td><td align="center" valign="bottom">0.0042±0.0001</td><td align="center" valign="bottom">0.79±0.03</td></tr></tbody></table></table-wrap><p>We also monitored the mantATP single turnover rate constants in WT and E525K M2β S1. We found that the slow phase that represents the SRX state was a small fraction of the fluorescence transients (~5%), was similar in WT and E525K, and was independent of ionic strength (<xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3A-C</xref>, <xref ref-type="table" rid="table3">Table 3</xref>). The rate constants of the SRX and DRX states were two- to fourfold faster in E525K compared to WT M2β S1 (<xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3D</xref>, <xref ref-type="table" rid="table3">Table 3</xref>). The rate constants for the DRX state were faster for S1 compared to 15HPZ.GFP in both WT and E525K, while only the mutant also had a faster SRX rate constant in S1 compared to 15HPZ.GFP (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3E–F</xref>). Our results demonstrate a larger increase in DRX rates for S1 constructs compared to 15HPZ.GFP than previously reported by <xref ref-type="bibr" rid="bib45">Rohde et al., 2018</xref> in proteolytically prepared bovine cardiac HMM. The reasons for this difference are unclear, but they are not due to protein quality based on the NH<sub>4</sub> ATPase results which demonstrate nearly identical ATPase values for S1 and 15HPZ.GFP HMM.</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Summary of single mantATP turnover measurements for WT and E525K M2β S1 (N=3, ± SD).</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Conditions</th><th align="center" valign="bottom">Disordered relaxed (DRX) rate</th><th align="center" valign="bottom">DRX fraction</th><th align="center" valign="bottom">Super-relaxed (SRX) rate</th><th align="center" valign="bottom">SRX fraction</th></tr><tr><th align="left" valign="bottom" colspan="5">WT</th></tr></thead><tbody><tr><td align="char" char="." valign="bottom">20 mM KCl</td><td align="center" valign="bottom">0.039±0.002</td><td align="center" valign="bottom">0.95±0.03</td><td align="center" valign="bottom">0.0075±0.0074</td><td align="center" valign="bottom">0.05±0.03</td></tr><tr><td align="char" char="." valign="bottom">50 mM KCl</td><td align="center" valign="bottom">0.036±0.003</td><td align="center" valign="bottom">0.98±0.01</td><td align="center" valign="bottom">0.0058±0.0045</td><td align="center" valign="bottom">0.02±0.01</td></tr><tr><td align="char" char="." valign="bottom">75 mM KCl</td><td align="center" valign="bottom">0.034±0.003</td><td align="center" valign="bottom">0.97±0.01</td><td align="center" valign="bottom">0.0082±0.0033</td><td align="center" valign="bottom">0.03±0.01</td></tr><tr><td align="char" char="." valign="bottom">100 mM KCl</td><td align="center" valign="bottom">0.032±0.003</td><td align="center" valign="bottom">0.97±0.01</td><td align="center" valign="bottom">0.0078±0.0047</td><td align="center" valign="bottom">0.03±0.01</td></tr><tr><td align="char" char="." valign="bottom">150 mM KCl</td><td align="center" valign="bottom">0.028±0.002</td><td align="center" valign="bottom">0.97±0.01</td><td align="center" valign="bottom">0.0044±0.0030</td><td align="center" valign="bottom">0.03±0.01</td></tr><tr><th align="left" valign="bottom" colspan="5">E525K</th></tr><tr><td align="char" char="." valign="bottom">20 mM KCl</td><td align="center" valign="bottom">0.085±0.005</td><td align="center" valign="bottom">0.94±0.03</td><td align="center" valign="bottom">0.0197±0.0025</td><td align="center" valign="bottom">0.06±0.03</td></tr><tr><td align="char" char="." valign="bottom">50 mM KCl</td><td align="center" valign="bottom">0.080±0.005</td><td align="center" valign="bottom">0.95±0.01</td><td align="center" valign="bottom">0.0204±0.0048</td><td align="center" valign="bottom">0.05±0.01</td></tr><tr><td align="char" char="." valign="bottom">75 mM KCl</td><td align="center" valign="bottom">0.076±0.006</td><td align="center" valign="bottom">0.94±0.04</td><td align="center" valign="bottom">0.0233±0.0012</td><td align="center" valign="bottom">0.06±0.04</td></tr><tr><td align="char" char="." valign="bottom">100 mM KCl</td><td align="center" valign="bottom">0.071±0.005</td><td align="center" valign="bottom">0.96±0.01</td><td align="center" valign="bottom">0.0185±0.0045</td><td align="center" valign="bottom">0.04±0.01</td></tr><tr><td align="char" char="." valign="bottom">150 mM KCl</td><td align="center" valign="bottom">0.074±0.018</td><td align="center" valign="bottom">0.97±0.02</td><td align="center" valign="bottom">0.0129±0.0026</td><td align="center" valign="bottom">0.03±0.02</td></tr></tbody></table></table-wrap></sec><sec id="s2-4"><title>Cy3ATP binding to M2β 15HPZ.GFP monitored by FRET</title><p>We first tested the FRET biosensor by examining the fluorescence emission spectra of M2β 15HPZ.GFP in the presence or absence of Cy3ATP in low- (20 mM KCl) and high-salt (150 mM KCl) conditions. We observed donor quenching at low salt (5–10%) in the presence of the acceptor that was attenuated at high salt and a similar trend by monitoring acceptor enhancement (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). We further characterized the IHM FRET biosensor by mixing Cy3ATP (0.25–2.5 µM) with M2β 15HPZ.GFP (0.25 µM) in a stopped-flow apparatus and monitoring the quenching of the GFP fluorescence as a function of time. The approach allowed us to measure the degree of donor quenching (amplitude) as well as the rate constants for Cy3ATP binding (<italic>k</italic><sub>obs</sub>) to M2β 15HPZ.GFP. The FRET transients clearly demonstrated donor quenching in the presence of the acceptor, while donor only controls exhibited no change in fluorescence (<xref ref-type="fig" rid="fig4">Figure 4A&amp;B</xref>). We reasoned that if more myosin heads were in the IHM conformation, we would observe a higher FRET efficiency. The fluorescence transients fit well to a two-exponential function especially at low salt (20–75 mM KCl) with some fitting better to a single exponential function at higher salt (100–150 mM KCl; <xref ref-type="fig" rid="fig4">Figure 4A&amp;B</xref>). We plotted the total amplitude of the FRET change upon Cy3ATP binding as a function of Cy3ATP concentration and found that WT had a smaller total amplitude at high salt (150 mM) compared to low salt (20 mM; <xref ref-type="fig" rid="fig4">Figure 4C</xref>). However, the total amplitudes with the E525K experiments were quite insensitive to KCl concentration (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), suggesting more M2β 15HPZ.GFP molecules were in the IHM conformation at higher salt. All of the rate constants were linearly dependent on Cy3ATP concentration (<xref ref-type="fig" rid="fig4">Figure 4E and F</xref>), suggesting they represent second-order rate constants for ATP binding (<xref ref-type="table" rid="table4">Table 4</xref>). The relative amplitude of the fast phase was higher in WT (65%) than E525K (25%) at low salt (<xref ref-type="table" rid="table4">Table 4</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>). Overall, the IHM FRET experiments followed a similar trend compared to the single ATP turnover experiments, suggesting the SRX biochemical state correlates with the IHM structural state.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Cy3ATP binding to M2β 15HPZ.GFP monitored by FRET.</title><p>GFP fluorescence (0.25 µM; donor) quenching was examined upon Cy3ATP (1 µM; acceptor) binding to WT (<bold>A</bold>) or E525K (<bold>B</bold>) M2β 15HPZ.GFP. The fluorescence transients were best fit to a double-exponential function at low salt (20 mM KCl) and a single or double exponential function at high salt (150 mM KCl; fast phase was 65% and 25% of the signal at low salt in WT and E525K, respectively). Residuals are shown above each plot. The total amplitude of the fluorescence change was plotted as a function of Cy3ATP concentration in WT (<bold>C</bold>) and E525K (<bold>D</bold>). All rate constants were linearly dependent on Cy3ATP concentration in both WT (<bold>E</bold>) and E525K (<bold>F</bold>) M2β 15HPZ.GFP (see <xref ref-type="table" rid="table4">Table 4</xref> for summary of linear fits in panel E and F). Each data point in C–F represents 2–3 replicates from a single preparation of myosin, and errors bars indicate ± SE of the fit.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Excel files with data from <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77415-fig4-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77415-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Steady-state FRET spectra.</title><p>Fluorescence emission spectra of WT M2β–15HPZ.GFP in the presence and absence of acceptor (Cy3ATP) were examined by exciting the sample at 470 nm and measuring the emission from 480 to 625 nm. (<bold>A</bold>) Fluorescence spectra of the donor highlight the donor quenching in the presence of Cy3ATP which was reduced at higher salt. (<bold>B</bold>) Fluorescence spectra of the acceptor, after subtracting donor fluorescence, highlight the acceptor enhancement in low- and high-salt conditions. Cy3ATP alone (absence of myosin) is shown for comparison.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Excel files with data from <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77415-fig4-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77415-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Amplitudes for Cy3ATP binding to M2β 15HPZ.</title><p>GFP. The amplitudes of the fast and slow components of the FRET transients examined in 20 mM (<bold>A and B</bold>) and 150 mM (<bold>C and D</bold>) KCl were plot as a function of Cy3ATP concentration (see <xref ref-type="fig" rid="fig4">Figure 4</xref>). Each data point represents a fluorescence transient (average of 2–3 replicates) that was fit to either a single or double exponential function (see source date for fit parameters). Error bars represent ± SEM.</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>Excel files with data from <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77415-fig4-figsupp2-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77415-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 3.</label><caption><title>Kinetic models of interacting-heads motif (IHM) formation based on stopped-flow FRET.</title><p>Two kinetic schemes (Scheme 1 and 2) were considered for modeling the kinetics of IHM formation. In Scheme 1, we assumed the initial ATP-binding step (K<sub>T</sub>) was followed by transition into the IHM (K<sub>IHM</sub>) which was then detected by FRET. The model postulates that heavy meromyosin (HMM) can populate two conformations in the absence of nucleotide (Apo), one that is in the Open conformation and another in an Alternate (ALT) conformation. The top pathway (Fast Phase-green) represents ATP binding to the Open state followed by a favorable transition into the IHM in low salt. The lower pathway (Slow Phase-yellow) is only significantly populated at low salt and characterized by slower ATP binding to the ALT conformation and a favorable transition into the IHM. In Scheme 2, the slow phase is caused by a conformation that is incompetent to bind nucleotide (INC) and in equilibrium with the Open conformation. In both models, in the absence of nucleotide (Apo) in low-salt conditions, the E525K mutant favors the ALT or INC conformation, while WT favors the open conformation. Also, both models predict that in high-salt conditions, the rate of transition into the IHM slows for both WT and mutant, and it is unfavorable for WT but E525K still favors the IHM. Rate constants for WT are in black and E525K in red (see <xref ref-type="table" rid="table4">Table 4</xref> for summary of rate constants).</p><p><supplementary-material id="fig4s3sdata1"><label>Figure 4—figure supplement 3—source data 1.</label><caption><title>Excel files with data from <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77415-fig4-figsupp3-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77415-fig4-figsupp3-v1.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 4.</label><caption><title>FRET transients fit to the proposed kinetic model.</title><p>The fluorescence transients from the FRET experiments are fit to the kinetic model described in <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>. The values of the rate and equilibrium constants are described in the legend of <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>. The ATP-binding rates determined from the linear fit of the rate constants as a function of Cy3ATP concentration were held constant (k<sub>+T</sub> and k’<sub>+T</sub> µM<sup>–1</sup>∙s<sup>–1</sup>) (see <xref ref-type="table" rid="table4">Table 4</xref>) and the rate and equilibrium constants for the transition into the interacting-heads motif (IHM) (K<sub>IHM</sub> and K’<sub>IHM</sub>) we allowed to float to best fit the transients. We conclude that under the conditions of the experiments, the FRET was limited by the rate of ATP binding, and thus, the transition into the IHM was ≥5 s<sup>–1</sup>.</p><p><supplementary-material id="fig4s4sdata1"><label>Figure 4—figure supplement 4—source data 1.</label><caption><title>Excel files with data from <xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77415-fig4-figsupp4-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77415-fig4-figsupp4-v1.tif"/></fig></fig-group><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Summary of kinetic parameters from Cy3ATP binding experiments.</title><p>(N=1,± SE of the fit).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Parameter</th><th align="center" valign="bottom">WT</th><th align="center" valign="bottom">E525K</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>k</italic><sub>fast</sub> (20 mM KCl) (µM<sup>–1</sup> s<sup>–1</sup>)</td><td align="center" valign="bottom">1.9±0.1</td><td align="center" valign="bottom">1.4±0.1</td></tr><tr><td align="left" valign="bottom"><italic>k</italic><sub>slow</sub> (20 mM KCl) (µM<sup>–1</sup> s<sup>–1</sup>)</td><td align="center" valign="bottom">0.15±0.01</td><td align="center" valign="bottom">0.06±0.01</td></tr><tr><td align="left" valign="bottom"><italic>A<sub>fast</sub></italic> (20 mM KCl)</td><td align="center" valign="bottom">0.65±0.04</td><td align="center" valign="bottom">0.25±0.05</td></tr><tr><td align="left" valign="bottom"><italic>k</italic><sub>fast</sub> (150 mM KCl) (µM<sup>–1</sup> s<sup>–1</sup>)</td><td align="center" valign="bottom">0.40±0.02</td><td align="center" valign="bottom">0.45±0.02</td></tr><tr><td align="left" valign="bottom"><italic>k<sub>slow</sub></italic> (150 mM KCl) (s<sup>–1</sup>)</td><td align="center" valign="bottom">0.06±0.03</td><td align="center" valign="bottom">0.12±0.06</td></tr><tr><td align="left" valign="bottom"><italic>A<sub>fast</sub></italic> (150 mM KCl)</td><td align="center" valign="bottom">0.81±0.03</td><td align="center" valign="bottom">0.89±0.16</td></tr></tbody></table></table-wrap><p>The kinetic results can be interpreted with two possible mechanisms (<xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>). In the first mechanism (Scheme 1), HMM can adopt two conformations in the absence of nucleotide (Apo), one that binds ATP with a similar rate constant to S1 (referred to as Open) and another that binds ATP more slowly (referred to as alternate conformation, ALT). Once the Open conformation binds ATP (K<sub>T</sub>), it rapidly transitions into the IHM (K<sub>IHM</sub>). In this pathway, ATP binding, followed by rapid transition into the IHM, gives rise to the fast phase of the FRET transients. The alternative conformation binds ATP about 10–20-fold slower (K’<sub>T</sub>) and then can rapidly transition into the IHM (K’<sub>IHM</sub>), thus giving rise to the slow phase that is also ATP concentration dependent. In this model, FRET is observed only in the IHM. Representative fluorescence transients from experiments with WT and E525K at low- and high-salt fit reasonably well to this kinetic model (<xref ref-type="fig" rid="fig4s4">Figure 4—figure supplement 4</xref>). Another possible mechanism is that HMM can undergo a slow isomerization between two conformations in the Apo state, an alternative conformation incompetent to bind nucleotide (INC) and an Open conformation (Scheme 2). In this model, the slow phase is caused by the slow isomerization into the Open state prior to ATP binding. This mechanism was originally proposed by <xref ref-type="bibr" rid="bib20">Geeves et al., 2000</xref> in a study on Myo1C and was since demonstrated in several other studies (<xref ref-type="bibr" rid="bib1">Adamek et al., 2010</xref>; <xref ref-type="bibr" rid="bib13">Clark et al., 2005</xref>; <xref ref-type="bibr" rid="bib63">Ušaj and Henn, 2017</xref>). Both models predict the E525K mutant stabilizes an alternate or incompetent Apo conformation at low salt, which explains the higher percentage of the slow phase observed in E525K. In addition, both models predict that high-salt favors the open Apo conformation in WT and mutant, while the transition into the IHM is unfavorable for WT but favorable for E525K.</p></sec><sec id="s2-5"><title>Steady-state and time-resolved FRET measurements</title><p>The stopped-flow fluorescence transients were also used to determine the FRET efficiency after performing donor only controls. Measuring a precise distance by FRET can be quite challenging and is most accurate when the distance is between 0.5 and 1.5 R<sub>0</sub> (31.5–94.5 Å). Since we predicted our closest distance in the IHM is ~100 Å (<xref ref-type="fig" rid="fig1">Figure 1</xref>), we emphasize our FRET approach is best utilized for measuring the change in FRET associated with different KCl concentrations and comparing WT and E525K, while it is not appropriate for measuring precise distances. We measured the FRET efficiency (0.25 µM M2β and 1 µM Cy3ATP) as a function of KCl concentration and found that WT shifts to a lower FRET state at higher KCl concentrations, while E525K maintains a similar FRET efficiency at low and high salt (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). We then compared the measured FRET efficiencies to the expected efficiencies assuming a simplified model in which the fraction of molecules in the closed and open states directly correlates with the single turnover measurements (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). We assumed no FRET in the open state and a FRET efficiency of ~6.0% associated with a 100 Å distance when all heads are in the IHM configuration. The expected FRET efficiencies followed a similar trend to the measured efficiencies, especially in the E525K mutant, while the largest discrepancies were observed with WT in higher salt conditions. This is likely due to the greater degree of uncertainty with the measurements at high salt, which contained the lowest FRET efficiencies.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>FRET monitors stability of the closed (interacting-heads motif [IHM]) conformation.</title><p>Steady-state FRET between the C-terminal GFP tag and Cy3ATP bound to the motor domain was examined in the stopped-flow as a function of KCl concentration. (<bold>A</bold>) The average FRET efficiency (± SD) was examined in three separate protein preparations. (<bold>B</bold>) The FRET efficiency in panel A was compared to the predicted FRET efficiency, based on the single turnover measurements in <xref ref-type="fig" rid="fig3">Figure 3</xref>. Error bars in panels A and B are ± SD, N=3 separate protein preparations with three technical replicates per prep. (<bold>C</bold>) Time-resolved FRET was examined by monitoring the GFP fluorescence lifetime in the presence and absence of Cy3ATP. Summary of fluorescence lifetime data with WT and E525K M2β 15HPZ.GFP. Adding saturating ATP to the sample containing WT M2β 15HPZ.GFP and Cy3ATP (ATP chase) was used to rule out donor fluorescence changes in the presence of ATP. (<bold>D</bold>) Time-resolved FRET (three technical replicates performed with a single protein preparation) demonstrated similar results to steady-state FRET shown in panel A (*p&lt;0.05 comparing WT and E525K, unpaired Student’s t-test).</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Excel files with data from <xref ref-type="fig" rid="fig5">Figure 5</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77415-fig5-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77415-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Representative fluorescence lifetime decays for TR-FRET analysis.</title><p>Fluorescence lifetime decays were collected by exciting the donor (GFP) using a 479 nm picosecond laser and examining donor fluorescence emission (515 long-pass filter) in the presence and absence of acceptor (Cy3ATP). Time-correlated single photon counting was used to collect lifetime decays. The donor only (60 nM M2β 15HPZ.GFP) is compared to the donor+acceptor (60 nM M2β 15HPZ.GFP+0.1 µM Cy3ATP) in 20 mM KCl conditions in WT (panel <bold>A</bold>) and E525K (panel <bold>B</bold>) M2β 15 HZ.GFP. The residuals are shown above the fits. The decays were fit well to a two-exponential function to determine the average lifetime (see <xref ref-type="fig" rid="fig5">Figure 5C</xref> for summary of average lifetime decay values and source data for all lifetime decay fit parameters).</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Excel files with data from <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77415-fig5-figsupp1-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77415-fig5-figsupp1-v1.tif"/></fig></fig-group><p>We also performed time-resolved FRET to further verify the differences we observed between WT and E525K (<xref ref-type="fig" rid="fig5">Figure 5C and D</xref>). Time-resolved FRET relies on monitoring the donor fluorescence lifetime decay in the presence and absence of acceptor and thus is less sensitive to sample-to-sample variability in fluorophore concentration. We examined the GFP fluorescence lifetime (60 nM M2β 15HPZ.GFP) in the absence of nucleotide and then again after adding 0.1 µM Cy3ATP (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). We then added saturating unlabeled ATP (1 mM) to chase off the Cy3ATP as a control for changes in donor fluorescence in the presence of ATP (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). The fluorescence decays were fit well to a two-exponential function which was used to determine the average lifetime in each condition (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). The donor fluorescence lifetimes were unaffected by the presence of ATP (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Overall, we found that the time-resolved and steady-state FRET measurements resulted in very similar FRET efficiencies (<xref ref-type="fig" rid="fig5">Figure 5A and D</xref>).</p></sec><sec id="s2-6"><title>Negative stain EM</title><p>WT and E525K M2β 15HPZ.GFP constructs were examined by negative stain EM to directly observe the impact of the mutation on the configuration of the myosin heads and to test our interpretation of the FRET data. Because the IHM is easily disrupted by binding to the grid surface during specimen preparation (<xref ref-type="bibr" rid="bib9">Burgess et al., 2007</xref>), we examined the molecules in low-salt (20 mM KCl) conditions, which strengthen the IHM, and minimized the time of contact of protein with the grid before staining. We performed the analysis on three separate preparations. The comparison of WT and E525K for each individual replicate was performed on the same day using grids from the same batch, prepared identically (glow-discharge etc.) under the same ambient conditions of temperature and humidity. WT molecules were dominated by non-interacting heads, producing an ‘open’ conformation (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, yellow circles; <xref ref-type="fig" rid="fig6">Figure 6D</xref>), with only a small number of ‘closed’ (folded) IHM structures (<xref ref-type="fig" rid="fig6">Figure 6A</xref>, green circles; <xref ref-type="fig" rid="fig6">Figure 6D</xref>). In contrast, more of the E525K molecules adopted the folded (IHM) conformation (<xref ref-type="fig" rid="fig6">Figure 6B</xref>, green circles; <xref ref-type="fig" rid="fig6">Figure 6D</xref>). Each replicate was performed on a different day, therefore, with non-identical conditions between preps. This likely accounts for differences in numbers of molecules in open and closed configurations between preps, as we know that conformation is highly sensitive to grid surface properties. Despite the experimental ‘noise’ introduced by these factors, there was a clear and dramatic 3-4 fold increase in the number of closed conformations in E525K compared with WT, consistent with stabilization of the IHM by the mutation and with the FRET data (<xref ref-type="fig" rid="fig6">Figure 6D</xref>, <xref ref-type="table" rid="table5">Table 5</xref>). Because of the strong influence of grid surface properties on conformation, disrupting the weak interactions of the IHM, a quantitative agreement with FRET data is not expected. For each prep of WT and E525K, a total of ~250–300 molecules were counted. Molecules that could be classified as open or closed were 70–85% of the total (<xref ref-type="table" rid="table5">Table 5</xref>); the remainder did not show a clearly identifiable structure (white circles in <xref ref-type="fig" rid="fig6">Figure 6A and B</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>EM structure of WT and E525K constructs.</title><p>(<bold>A</bold> and <bold>B</bold>) Negative stain images of WT and E525K, respectively, showing the conformational state of the molecules (yellow – open; green – closed; white circle – not clear/partially folded). (<bold>C</bold>) 2D class average of E525K, showing subdomains (<xref ref-type="fig" rid="fig1">Figure 1</xref>, ‘closed’). (<bold>D</bold>) Results of three biological replicate experiments comparing % of closed (interacting-heads motif [IHM]) conformations in WT and E525K. We attribute the variable results to unavoidable differences in grid surface characteristics on the different experimental days. Despite these differences, the same trend occurred in each experiment, with E525K showing 3-4 times as many IHMs as WT (see <xref ref-type="table" rid="table5">Table 5</xref> for summary, N=250-300 molecules per preparation).</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Electron micrographs used for classifying molecules in the folded-back interacting-heads motif (IHM) or open conformation .</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-77415-fig6-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77415-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>2D class averaging of M2β 15HPZ.</title><p>GFP negative stain images. (<bold>A</bold>) WT and (<bold>B</bold>) E525K. The numeral in each panel indicates the number of particles contributing to the particular class average. (<bold>C–E</bold>) Superposition of M2β 15HPZ.GFP atomic model on E525K class average. (<bold>C</bold>) Class average. (<bold>D</bold>) Atomic model based on 5tby (<xref ref-type="fig" rid="fig1">Figure 1</xref>). (<bold>E</bold>) Superposition, demonstrating good agreement between EM imaging and model, supporting our identification of the molecules as bona fide interacting-heads motifs (IHMs).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77415-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Potential intramolecular interactions of E525K with S2.</title><p>Top left: oblique view of folded myosin hexamer from the C-terminal end. Note C-terminal GFP molecules for orientation of molecule with blocked head (BH, cyan) and free head (FH, orange) of myosin. Inset: potential intramolecular interactions between the mutated 525 K residue (blue, positively charged amine group) on BH of myosin with nearby acidic residues on S2 (red, negatively charged carboxylic acids) of both BH and FH. Highlighted residues include E902 on S2 of BH and E894 and D896 on S2 of FH. Intramolecular interactions were mapped using UCSF Chimera on same closed structure (5TBY template) described in <xref ref-type="fig" rid="fig1">Figure 1</xref> (<xref ref-type="bibr" rid="bib5">Alamo et al., 2017</xref>; <xref ref-type="bibr" rid="bib42">Pettersen et al., 2004</xref>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-77415-fig6-figsupp2-v1.tif"/></fig></fig-group><table-wrap id="table5" position="float"><label>Table 5.</label><caption><title>Summary of negative stain EM images classified as open vs. closed conformation.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Preparation</th><th align="left" valign="top">WT(% closed)</th><th align="left" valign="top">WT(% open)</th><th align="left" valign="top">E525K(% closed)</th><th align="left" valign="top">E525K(% open)</th><th align="left" valign="top">% E525K closed/% WT closed</th></tr></thead><tbody><tr><td align="char" char="." valign="top">1</td><td align="char" char="." valign="top">16.9</td><td align="char" char="." valign="top">83.1</td><td align="char" char="." valign="top">56.9</td><td align="char" char="." valign="top">43.1</td><td align="char" char="." valign="top">3.4</td></tr><tr><td align="char" char="." valign="top">2</td><td align="char" char="." valign="top">8.5</td><td align="char" char="." valign="top">91.5</td><td align="char" char="." valign="top">34.8</td><td align="char" char="." valign="top">65.2</td><td align="char" char="." valign="top">4.1</td></tr><tr><td align="char" char="." valign="top">3</td><td align="char" char="." valign="top">6.5</td><td align="char" char="." valign="top">93.5</td><td align="char" char="." valign="top">27.0</td><td align="char" char="." valign="top">73.0</td><td align="char" char="." valign="top">4.2</td></tr></tbody></table></table-wrap><p>To validate our assessment of open and closed percentages based on visual inspection of the raw micrographs (<xref ref-type="fig" rid="fig6">Figure 6A, B and D</xref>), we performed 2D class averaging of the molecules using Relion 3.1 (<xref ref-type="bibr" rid="bib49">Scheres, 2012</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). The class averages clearly show that in the case of E525K, more of the molecules form the IHM conformation when compared with WT (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A and B</xref>). We also used class averaging to confirm that the closed structures we observed were actually IHMs. The E525K class average shown in <xref ref-type="fig" rid="fig6">Figure 6C</xref> reveals key features of the IHM, including the BHs and FHs, the two light chains (essential light chains, ELCs, and regulatory light chains, RLCs), and sub-fragment 2 interacting with the BH, all well-documented features of the IHM (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1C–E</xref>). We conclude that the raw EM images and the 2D class averages qualitatively support our ATP turnover and FRET results showing that E525K promotes the IHM and thus stabilizes the SRX state.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>A common mechanism of myosin II regulation is via folding of the heads back onto the tail and interaction between the motor domains, effectively inhibiting actomyosin interactions and myosin ATP turnover. In the current study, we investigated the regulatory mechanism in cardiac muscle myosin, which exists in dynamic equilibrium between the folded-back conformation (IHM) and an open conformation capable of generating force upon muscle activation (<xref ref-type="fig" rid="fig1">Figure 1</xref>). A major question in the field is whether the IHM correlates with the SRX state, a biochemical state that turns over ATP 5–10-fold slower than single-headed S1. This proposed mechanism is attractive since the sequestered heads would inhibit interactions with actin, serving as a reserve to be recruited when enhanced contractile force is needed (e.g. length-dependent activation). Furthermore, sequestered heads would consume far less ATP, helping to balance the energetic demands of the heart. We present direct evidence that the fraction of myosin heads in the IHM correlates well with the fraction of myosin heads in the SRX state, providing crucial information about the structural basis of the auto-inhibited state of cardiac myosin. We also demonstrate that a dimeric cardiac myosin molecule with 15 heptads of the coiled-coil displays the SRX state and IHM structure, allowing us to examine the folded conformation with a novel IHM FRET biosensor. In addition, we report that a single point mutation associated with DCM (E525K) can dramatically stabilize both the IHM conformation and SRX state. Our work highlights the stabilization of the IHM by electrostatic interactions and the critical function of the E525 residue in the core region where electrostatic interactions between the head and tail occur. The clinical significance of this study is that a DCM mutation can stabilize the auto-inhibited state of myosin, which provides a strong rationale for studying other DCM mutants to determine if this is a common mechanism that causes the reduced muscle force and power typically observed in DCM patients.</p><sec id="s3-1"><title>Correlating the SRX and IHM</title><p>The current study provides new information about the structural basis of the slow ATP turnover (SRX) state. Previously, <xref ref-type="bibr" rid="bib8">Anderson et al., 2018</xref> demonstrated a strong correlation between the IHM and SRX state using negative stain EM and single ATP turnover measurements. They also examined the drug mavacamten, which dramatically stabilizes the SRX state. Based on visual inspection of negative stained EM images, they observed a corresponding increase in the fraction of molecules that adopt the IHM in the presence of the drug. Our study used single turnover measurements, in addition to an IHM FRET biosensor, to examine the conformation of cardiac myosin in solution. The fraction of myosin heads in the SRX state determined by single turnover measurements was used to simulate the FRET results expected if the SRX state and IHM are 1–1 correlated (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). We generated FRET efficiency estimates based on the structural model shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>, which predicts the average distance between donor-acceptor pairs in the IHM is in the range of 90–140 Å and no FRET in the open state. The measured FRET efficiency (5.5%) observed in low-salt conditions (<xref ref-type="fig" rid="fig5">Figure 5A</xref>) corresponded to a condition with nearly 90% SRX heads (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="table" rid="table2">Table 2</xref>), which allowed us to assume an efficiency of 6.0% in the IHM for our simulations. The simulated data follows fairly closely with the measured FRET efficiencies for the mutant but diverges for WT at higher salt (≥100 mM KCl; <xref ref-type="fig" rid="fig5">Figure 5B</xref>), likely because the fraction of myosin heads in the IHM is quite low (≤10%) in high-salt conditions and difficult to measure by FRET. Future experiments using time-resolved FRET approaches such as TR(2)-FRET (<xref ref-type="bibr" rid="bib22">Gunther et al., 2019</xref>; <xref ref-type="bibr" rid="bib45">Rohde et al., 2018</xref>) may allow us to determine distance distributions, distances associated with partially folded intermediates, and the rate constants for transitioning into and out of the IHM.</p><p>Another study performed single turnover measurements with a different IHM FRET biosensor in bovine cardiac myosin and found the IHM was sufficient but not required to produce the SRX state (<xref ref-type="bibr" rid="bib12">Chu et al., 2021</xref>). They used glutaraldehyde cross linking to stabilize the IHM and found a corresponding increase in FRET. They demonstrated that mavacamten dramatically stabilizes the SRX state but did not cause a corresponding increase in the IHM formation, suggesting that the biochemical SRX state and structural IHM are uncoupled. Importantly, their FRET approach was not sensitive to ionic strength, which is very different from our results and other previous IHM studies. Other groups also have demonstrated that myosin constructs that lack an S2 domain, such as S1 and 2HP HMM (and thus cannot form the IHM), still have a small SRX state component in single turnover measurements (<xref ref-type="bibr" rid="bib8">Anderson et al., 2018</xref>; <xref ref-type="bibr" rid="bib45">Rohde et al., 2018</xref>). Our results fit well with the hypothesis that the SRX state may not require the formation of the IHM, but the IHM certainly enhances the SRX state by stabilizing the SRX heads (<xref ref-type="bibr" rid="bib16">Craig and Padrón, 2022</xref>). The fraction of SRX heads also depends on their supramolecular organization, with the SRX molecules increasing from M2β S1 to HMM to a thick filament (<xref ref-type="bibr" rid="bib16">Craig and Padrón, 2022</xref>). This relationship accounts for nominal SRX ratios observed in S1 and 2HP HMM as well as the correlation between SRX and IHM in our M2β HMM 15HPZ.GFP biosensor. Moreover, it accounts for the high sensitivity of the SRX state to ionic strength in HMM since many of the proposed interactions in the IHM are electrostatic in nature.</p><p>In addition to using FRET to monitor IHM formation, we examined negative stain EM images of M2β HMM 15HPZ.GFP, both by direct visual inspection and 2D class averaging, which allowed us to systematically classify the fraction of molecules in the IHM. We found that the E525K mutant had a much higher fraction of myosin heads in the IHM compared to WT (<xref ref-type="fig" rid="fig6">Figure 6</xref>). However, this fraction was significantly different in the EM images compared to the predictions from the FRET and single turnover measurements in solution. We believe this is due to molecular interactions with the EM grid surface that destabilize the IHM. This has been well documented with smooth muscle HMM (<xref ref-type="bibr" rid="bib9">Burgess et al., 2007</xref>). Our similar but even more extreme finding with cardiac myosin is exactly as predicted, given the lower stability of the cardiac compared with the smooth muscle myosin IHM (<xref ref-type="bibr" rid="bib26">Jung et al., 2008</xref>). In fact, we found it essential to reduce the time of contact of the cardiac construct with the grid surface to a minimum (~5 s) before adding the uranyl acetate stain, which then immediately fixes the structure (<xref ref-type="bibr" rid="bib78">Zhao and Craig, 2003</xref>). With longer contact times, almost all IHMs were lost, consistent with the smooth muscle HMM findings (<xref ref-type="bibr" rid="bib9">Burgess et al., 2007</xref>). Indeed, a recent study that performed small angle x-ray scattering on a cardiac myosin 25 heptad construct found that alternative conformations are likely in solution, including partially folded intermediates (e.g. one head folded and one head free; <xref ref-type="bibr" rid="bib21">Gollapudi et al., 2021</xref>). We observed many structures by 2D class averaging with different orientations of heads. However, it is difficult to distinguish between novel conformations and states that simply lie on the grid in different orientations. Overall, our work clearly demonstrates by both EM and FRET that the IHM is a major contributor to the SRX state, while our EM studies suggest that the IHM is quite dynamic and sensitive to surface interactions.</p></sec><sec id="s3-2"><title>Kinetics of IHM formation</title><p>One unanswered question is how fast various myosins can transition into and out of the IHM. Geeves and co-workers estimated the rate of transition into the IHM was at least 5 s<sup>–1</sup> in bovine cardiac myofibrils (<xref ref-type="bibr" rid="bib66">Walklate et al., 2022</xref>). In agreement, our results suggest the transition into the IHM was significantly faster than ATP binding (≥5 s<sup>–1</sup>; <xref ref-type="fig" rid="fig4">Figure 4</xref>). Our results also suggest there are two conformations of HMM in the absence of nucleotide, one that binds ATP similar to S1 (Open) and one that binds ATP about 10–20-fold slower (ALT; see <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>). We also found that high salt shifts the equilibrium toward the Open conformation in the absence of nucleotide for both WT and E525K, while only the mutant can transition efficiently into the IHM upon ATP binding. Alternatively, the data may suggest that there is an isomerization between competent and incompetent states in the absence of nucleotide, which has been proposed to explain the bi-exponential kinetics of ATP binding to myosin in previous studies (<xref ref-type="bibr" rid="bib20">Geeves et al., 2000</xref>; see <xref ref-type="fig" rid="fig4s3">Figure 4—figure supplement 3</xref>). Thus, further work will be necessary to define the specific structural and kinetic pathway for transition into and out of the IHM, and current and future IHM FRET biosensors could lead the way in this important area of study.</p></sec><sec id="s3-3"><title>Structural mechanism of IHM and impact of E525K</title><p>Presently, there is no high-resolution structure of the cardiac myosin IHM. The work of Padrón and colleagues has created a model based on the tarantula thick filaments (5TBY) but using the human cardiac myosin sequence, which has been extremely useful for mapping potential head-head and head-tail interactions (<xref ref-type="bibr" rid="bib5">Alamo et al., 2017</xref>). The recent cryo-EM structures of smooth muscle myosin in the 10 S conformation provide more models of the IHM, which have some similarities and some differences compared to 5TBY (<xref ref-type="bibr" rid="bib23">Heissler et al., 2021</xref>; <xref ref-type="bibr" rid="bib47">Scarff et al., 2020</xref>; <xref ref-type="bibr" rid="bib74">Yang et al., 2020</xref>).</p><p>The E525K mutation was identified in a genetic study as a de novo variant of high clinical significance (<xref ref-type="bibr" rid="bib30">Lakdawala et al., 2012a</xref>). Previous structural analysis of cardiac myosin further implicates the mutation due to its location on a flat, broad region of myosin known as the mesa (<xref ref-type="bibr" rid="bib51">Spudich, 2015</xref>). The E525 residue is located in the lower 50 kDa region of the myosin motor domain in Helix Q of the helix-loop-helix (<xref ref-type="bibr" rid="bib14">Colegrave and Peckham, 2014</xref>), which is known to be crucial for actin binding (<xref ref-type="bibr" rid="bib65">Várkuti et al., 2012</xref>). From the perspective of the myosin mesa, E525 is in the central region of the ‘mesa trail,’ a region of the mesa shown to interact directly with S2 in formation of the IHM (<xref ref-type="bibr" rid="bib37">Nag et al., 2017</xref>; <xref ref-type="bibr" rid="bib72">Woodhead and Craig, 2020</xref>). Electrostatic attraction between the mesa trail of the BH and S2 is believed to underlie a crucial BH/S2 priming interaction in the formation of the IHM (<xref ref-type="bibr" rid="bib5">Alamo et al., 2017</xref>). Previous structural analyses indicate that the central mesa trail (rich in positively charged residues) interacts with the Ring 1 region of S2 (rich in negatively charged residues), and these complementary charged patches likely encourage formation of the IHM. Disruption of the charge distribution in the BH/S2 interaction region could cause complete elimination of the IHM, promoting myosin heads to populate the open or force-generating state, as has been proposed with many HCM mutations (<xref ref-type="bibr" rid="bib46">Sarkar et al., 2020</xref>). E525 is a negatively charged residue within the positively charged mesa trail and may function normally to repel Ring 1/mesa interactions, helping maintain the delicate balance of attractive/repulsive forces required for the precise functioning of the IHM. A charge-reversal point mutation, such as E525K, that increases the positive surface charge of the mesa trail likely would strengthen the Ring 1/mesa interaction in the BH, thus promoting the formation of the IHM. Importantly, E525, as well as many other charged residues in the mesa trail and Ring 1 of S2, is well conserved across species and myosin isoforms, suggesting a critical role for electrostatic interactions between BH/S2 in the formation of the auto-inhibitory state (<xref ref-type="bibr" rid="bib72">Woodhead and Craig, 2020</xref>). Without a high-resolution structure of the cardiac muscle myosin IHM, specific side chain residues in the BH/S2 interaction have not been confirmed. However, our collective data presented here coupled with previous conservation analyses indicate that E525 may be a critical residue in forming the IHM. This is further supported by our molecular modeling of the IHM, in which the introduced lysine residue at 525 of the BH is within several Angstroms of several acidic residues in the S2 region (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>).</p><p>An alternative mechanism by which a mutation can enhance the formation of the IHM is by favoring a conformation of an intermediate that precedes IHM formation (e.g. allosteric mechanism). There is little information about the allosteric mechanisms that mediate IHM formation, while several studies have proposed that the pre-power stroke conformation of the motor domain may favor IHM formation (<xref ref-type="bibr" rid="bib5">Alamo et al., 2017</xref>; <xref ref-type="bibr" rid="bib44">Robert-Paganin et al., 2018</xref>). Our single turnover measurements with E525K and WT S1 suggest that they have a similar ability to populate the SRX state in S1 (~5%), and this small fraction of SRX formation is independent of ionic strength (<xref ref-type="fig" rid="fig3s3">Figure 3—figure supplement 3</xref>, <xref ref-type="table" rid="table3">Table 3</xref>). Therefore, we conclude that E525K enhances the IHM and SRX state via electrostatic interactions.</p></sec><sec id="s3-4"><title>Implications for understanding the underlying mechanisms of DCM</title><p>Determining mutation-associated alterations in cardiac muscle myosin structure and function can lead to novel therapeutic strategies for the treatment of inherited cardiomyopathies such as HCM and DCM. A leading hypothesis is that HCM mutations enhance myosin-associated force and power, while DCM mutations essentially do the opposite (<xref ref-type="bibr" rid="bib18">Debold et al., 2007</xref>; <xref ref-type="bibr" rid="bib50">Spudich, 2014</xref>). So far, mutations in myosin associated with HCM and DCM have been found to have diverse effects on myosin motor function, including altering ATPase activity, actin sliding velocity, duty ratio, and load dependence (<xref ref-type="bibr" rid="bib57">Trivedi et al., 2020</xref>; <xref ref-type="bibr" rid="bib62">Ujfalusi et al., 2018</xref>). However, HCM mutations have been shown to cluster preferentially in the head-head and head-tail interaction interfaces, likely weakening interactions that underlie the SRX state, leading to greater availability of heads for actin interaction and thus to hypercontractility (<xref ref-type="bibr" rid="bib56">Trivedi et al., 2018</xref>). The current study demonstrates that a DCM mutation can do just the opposite, dramatically stabilizing the SRX state, suggesting the possibility that other mutations may have a similar effect. A decrease in the number of available myosin heads in the thick filament would have a profound impact on contractile force and fit well with the hypocontractility hypothesis. Thus, therapeutic strategies that can destabilize the IHM and SRX state would be a logical strategy for treating DCM. However, unlike HCM, which primarily impacts sarcomeric genes, DCM is more heterogeneous and associated with a variety of genes (<xref ref-type="bibr" rid="bib75">Yotti et al., 2019</xref>). Nevertheless, treating DCM with an SRX state destabilizer may be feasible regardless of the underlying genetic cause since it could accomplish the overall goal of enhancing contractility. The E525K mutant provides great insight into an energy conservation mechanism that may underlie the development of the DCM phenotype in this patient population. Moreover, our data indicate that it can serve as a model mutation to deepen our understanding of the SRX biochemical state and IHM structural state in beta-cardiac myosin.</p><p>The E525K mutation clearly stabilizes the SRX state and IHM in the M2β 15HPZ.GFP construct, while it enhances the actin-activated ATPase activity in S1 (<xref ref-type="fig" rid="fig2">Figure 2A and B</xref>). Remarkably, the mutation’s ability to stabilize the IHM through electrostatic interactions between the BH and S2 seems to dominate the effects on ATPase activity in M2β 15HPZ.GFP. Future studies with M2β E525K S1 will investigate how this mutation structurally and biochemically enhances intrinsic actin-activated ATPase activity and impacts motile function. Other future investigations will examine how this intriguing mutation alters ensemble force production, given the enhanced intrinsic ATPase activity of the motor domain but dramatically stabilized SRX/IHM state in M2β 15HPZ.GFP.</p><p>It is important to point out some of the limitations and alternative interpretations of the results in the current study. The M2β 15HPZ.GFP was examined with mouse light chains intrinsic to the C2C12 myocyte expression system, which could alter the impact of the E525K mutation. It has been suggested that full-length myosin in a thick filament environment can further stabilize the SRX state through interactions of IHMs with each other along the helical tracks of heads and with other thick filament proteins (<xref ref-type="bibr" rid="bib16">Craig and Padrón, 2022</xref>). Interestingly, mutations measured in purified HMM qualitatively had the same impact on the SRX state in a thick filament preparation (<xref ref-type="bibr" rid="bib21">Gollapudi et al., 2021</xref>). The FRET approach is a biosensor of the IHM structural state, while the open state is not visible by FRET, preventing us from directly determining the mole fraction of the IHM and open states. The FRET distances in the current approach are not in the ideal range (0.5–1.5 R<sub>0</sub>) for measuring precise distances by FRET. Finally, EM provides a snapshot of a fraction of myosin molecules, while the solution measurements (single turnover and FRET) provide information on the entire ensemble. The EM studies also have the limitation that the charge of the EM grid can influence the stability of the IHM.</p></sec><sec id="s3-5"><title>Summary</title><p>In summary, we examined a human cardiac myosin construct with 15 heptads in its coiled coil and used EM imaging to show that it can form the conserved, auto-inhibited conformation known as the IHM. We also used a novel IHM FRET sensor to monitor the formation of the IHM in solution and determined that it correlates well with the SRX state with slow ATP turnover. Furthermore, we discovered that a DCM charge reversal mutation (E525K) in the motor-tail interface can greatly enhance the stability of the IHM conformation and SRX state. We conclude that this elegant method of regulation, which essentially sequesters myosin heads to balance the mechanical and energetic demands of the heart, is highly sensitive to modifications that alter the electrostatic interactions important for stabilizing the auto-inhibited conformation. Thus, future studies will investigate other DCM mutations that may also stabilize the IHM and SRX state as well as determine how other physiological factors and disease states alter this important regulatory mechanism.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Reagents</title><p>Cy3ATP (1 mM stock) and 2’-deoxy-ATP labeled with N-Methylanthraniloyl at the 3’-ribose position (mantATP; 10 mM stock) were purchased from Jena Biosciences. ATP and ADP were prepared from powder (MilliporeSigma), and concentrations were determined by absorbance at 259 nm (ε<sub>259</sub>=15,400 M<sup>–1</sup> cm<sup>–1</sup>). All assays were performed in MOPS 20 buffer (10 mM MOPS, pH 7.0, 20 mM KCl, 1 mM MgCl<sub>2</sub>, 1 mM EGTA, and 1 mM DTT) at 25°C unless otherwise noted.</p></sec><sec id="s4-2"><title>Protein expression and purification</title><p>The human beta-cardiac myosin 15 heptad HMM construct includes residues 1–946 of the <italic>MYH7</italic> gene (GenBank: AAA51837.1) with a leucine zipper GCN4 sequence (MKQLEDKVEELLSKNYHLENEVARLKKLVGER) added after residue 946, followed by a short linker (GSGKL), a C-terminal EGFP tag (M2β 15HPZ.GFP), Avi (GLNDIFEAQKIEWHE), and FLAG (DYKDDDDK) tags. Another construct was generated of just the S1 region which included residues 1–842 of the <italic>MYH7</italic> gene and C-terminal Avi and FLAG tags (<xref ref-type="bibr" rid="bib53">Swenson et al., 2017</xref>). The E525K mutation was introduced by Quikchange sited directed mutagenesis into M2β 15HPZ.GFP and M2β S1. The constructs were cloned into the pDual shuttle vector, and the initial recombinant adenovirus stock was produced by Vector Biolabs (Malvern, PA, USA) at a titer of 10<sup>8</sup> plaque forming units per mL (pfu mL<sup>−1</sup>). As previously described, the virus was expanded by infection of Ad293 cells at a multiplicity of infection of 3–5 (<xref ref-type="bibr" rid="bib53">Swenson et al., 2017</xref>). The virus was harvested from the cells and purified by CsCl density sedimentation, giving a final virus titer of 10<sup>10</sup>–10<sup>11</sup> pfu mL<sup>−1</sup>.</p><p>The mouse skeletal muscle derived C2C12 cell line was used to express the cardiac myosin constructs as described previously (<xref ref-type="bibr" rid="bib11">Chow et al., 2002</xref>; <xref ref-type="bibr" rid="bib53">Swenson et al., 2017</xref>; <xref ref-type="bibr" rid="bib67">Wang et al., 2003</xref>; <xref ref-type="bibr" rid="bib70">Winkelmann et al., 2015</xref>). Briefly, C2C12 cells were grown to ~90% confluency on tissue culture plates (145/20 mm) in growth media (DMEM with 9% FBS). On the day of infection, 20 plates were differentiated by changing the media to contain horse serum (DMEM with 9% horse serum, 1% FBS) and simultaneously infected with virus at 4×10<sup>7</sup> pfu mL<sup>−1</sup>. The cells were harvested for myosin purification 10–12 days after infection, and M2β constructs were purified by FLAG affinity chromatography. Actin was purified using acetone powder from rabbit skeletal muscle (<xref ref-type="bibr" rid="bib41">Pardee and Spudich, 1982</xref>).</p></sec><sec id="s4-3"><title>Steady-state ATPase assays</title><p>The actin-activated ATPase of 0.1 µM M2β in the presence and absence of actin (5, 10, 20, 40, and 60 µM) was examined in MOPS 20 buffer at 25°C with the NADH coupled assay as described in previous studies (<xref ref-type="bibr" rid="bib43">Rasicci et al., 2021</xref>; <xref ref-type="bibr" rid="bib53">Swenson et al., 2017</xref>; <xref ref-type="bibr" rid="bib54">Tang et al., 2021</xref>). The ATPase activity was plot as a function of actin concentration and fit to a Michaelis Menten equation to determine the maximum ATPase rate (<italic>k</italic><sub>cat</sub>) and actin concentration at which ATPase in one-half maximal (<italic>K</italic><sub>ATPase</sub>). At least three preparations (one technical replicate per prep) of each construct were examined.</p></sec><sec id="s4-4"><title>NH<sub>4</sub><sup>+</sup> ATPase assays</title><p>A high-salt ATPase assay was used to evaluate the number of active myosin heads in our preparations (M2βS1 and 15HPZ.GFP). The assay was performed at room temperature (22 ± 1°C) in NH<sub>4</sub><sup>+</sup> ATPase buffer (25 mM Tris. 0.4 M NH<sub>4</sub>Cl, 2 mM EDTA, and 0.2 M sucrose at pH 8.0) with 0.5 µM myosin and 3.8 mM NH<sub>4</sub><sup>+</sup>-ATP as previously described (<xref ref-type="bibr" rid="bib61">Trybus, 2000</xref>). Briefly, the amount of phosphate liberation as a function of time, determined with a colormetric method that detects phosphomolybdate, was determined by sampling the reaction every 2 min over a 10-min period. A standard curve with known phosphate concentrations was used to determine free phosphate concentration at each time point. The experiment was performed in triplicate with a single preparation of E525K and WT M2βS1 and 15HPZ.GFP.</p></sec><sec id="s4-5"><title>In vitro motility assays</title><p>The in vitro motility (IVM) assay was performed with WT and E525K M2β 15HPZ.GFP constructs, adapted from previously established protocols (<xref ref-type="bibr" rid="bib29">Kron et al., 1991</xref>; <xref ref-type="bibr" rid="bib43">Rasicci et al., 2021</xref>). Briefly, microscope cover slips were coated with 1% nitrocellulose in amyl acetate (Ladd Research) and applied to a microscope slide with double-sided tape to create a flow cell. Myosin in MOPS 20 buffer at concentrations between 72 and 90 µg mL<sup>−1</sup> (0.4–0.5 µM) was applied directly to the nitrocellulose surface, and the surface subsequently was blocked with BSA (1 mg mL<sup>−1</sup>). To ensure inactive myosin heads (‘dead heads’) were blocked, unlabeled sheared actin (2 µM) was added to the flow cell and chased with ATP (2 mM). Actin was labeled with phalloidin-Alexa 555 (DsRed filter; excitation/emission 555/588 nm). To initiate motility, an activation buffer containing 0.35% methylcellulose, an ATP regeneration system (2 mM ATP, 5 mg mL<sup>−1</sup> glucose, 46 units mL<sup>−1</sup> pyruvate kinase, and 0.46 mM phosphoenolpyruvate), and oxygen scavengers (0.1 mg mL<sup>−1</sup> glucose oxidase and 0.018 mg mL<sup>−1</sup> catalase) was added to the flow cell. Temperature (25 ± 1°C) was monitored using a thermocouple meter (Stable Systems International). The slide was visualized promptly with a NIKON TE2000 microscope equipped with a 60×/1.4 NA phase objective and a Perfect Focus System. All images were acquired at 1 s intervals for 2 min using a shutter controlled CoolSNAP HQ2 cooled CCD digital camera (Photometrics) binned 2×2. Videos were exported to ImageJ and prepared for automated FAST software motility analysis (<xref ref-type="bibr" rid="bib3">Aksel et al., 2015</xref>), from which &gt;1000 actin filaments from one experiment (i.e. slide) per protein preparation (N=3) at 0.4–0.5 µM myosin were compiled for statistical analysis, WT vs. E525K.</p></sec><sec id="s4-6"><title>Transient kinetic measurements</title><p>An Applied Photophysics stopped-flow equipped with an excitation monochromator, 1.2 ms dead-time, 9.3 nm band pass, and temperature control (25°C) was used for all experiments. Fluorescence transients were fit to sum of exponentials using the stopped-flow program or GraphPad Prism. For example, the following function was used to fit fluorescence decays, <inline-formula><mml:math id="inf1"><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow/></mml:msub></mml:math></inline-formula>, where <italic>F(t</italic>) is the fluorescence as a function of time <italic>t</italic>, F<sub>∞</sub> is the intensity at infinity, <italic>A</italic><sub>i</sub> is the amplitude, <italic>k<sub>i</sub></italic> is the observed rate constant characterized by the <italic>ith</italic> transition, and <italic>n</italic> is the total number of observed transitions.</p></sec><sec id="s4-7"><title>Single turnover measurements</title><p>The mant fluorescence was examined with 290 nm excitation and a 395 nm long pass emission filter. Myosin samples were incubated on ice for 10 min in the appropriate buffer conditions prior to each experiment. Single mantATP turnover experiments were performed by incubating M2β constructs (0.25 µM) with mantATP (1 µM) for 30 s at room temperature and then mixing the complex with saturating ATP (2 mM) and monitoring the fluorescence decay over a 1000 s period. The average ( ± SD) SRX ratio, SRX rate, and DRX rate were determined from three separate protein preparations (one technical replicate per preparation).</p></sec><sec id="s4-8"><title>Steady-state FRET measurements in fluorimeter</title><p>We examined the fluorescence spectrum of M2β 15HPZ.GFP (0.25 µM) in the presence and absence of Cy3ATP (1 µM) at 25°C in a fluorimeter equipped with excitation and emission monochromators (Photon Technology International). The sample was excited at 470 nm, and the emission spectra were measured from 480 to 625 nm. The emission spectra of the donor were corrected for photobleaching and dilution effects, and the emission spectra of the acceptor were also correct for donor fluorescence to visualize the changes in the acceptor spectra.</p></sec><sec id="s4-9"><title>Stopped-flow FRET measurements</title><p>Stopped-flow FRET was examined by monitoring the change in donor fluorescence (GFP) using an excitation wavelength of 470 nm and measuring the emission with an interference filter (500–525 nm), which eliminated background fluorescence from Cy3ATP. For measurement of the rate of Cy3ATP binding to M2β, we mixed M2β 15HPZ.GFP with varying concentrations of Cy3ATP (0.25–2.5), pre-equilibrated in MOPS buffer containing 20 or 150 mM KCl (2–3 technical replicates per condition with a single protein preparation). For determining the FRET efficiency as a function of KCl concentration, M2β 15HPZ.GFP (0.25 µM) was mixed with Cy3ATP (1 µM), pre-equilibrated in MOPS 20 buffer with varying KCl concentrations. The fluorescence transients, average of three replicates, were fit to a single or double exponential function, and the total amplitude of the fluorescence change was utilized to determine the degree of donor quenching in each experiment. The steady-state FRET efficiency (<italic>E</italic>) was calculated by examining donor quenching, after correcting for background fluorescence, using the following equation (<xref ref-type="bibr" rid="bib32">Lakowicz, 2006</xref>; <xref ref-type="bibr" rid="bib54">Tang et al., 2021</xref>),<disp-formula id="equ1"><mml:math id="m1"><mml:mrow><mml:mi>E</mml:mi><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>where <italic>F</italic><sub>DA</sub> is the donor fluorescence intensity in the presence of acceptor (under conditions of saturating Cy3ATP bound to M2β 15HPZ.GFP), and <italic>F</italic><sub>D</sub> is the donor fluorescence intensity in the absence of acceptor (M2β 15HPZ.GFP in the presence of ATP). The entire series of FRET experiments at each KCL concentration was repeated with three separate protein preparations to determine the average FRET efficiency. The distance (<italic>r</italic>) between the donor and acceptor was calculated based on the equation below (<xref ref-type="bibr" rid="bib32">Lakowicz, 2006</xref>),<disp-formula id="equ2"><mml:math id="m2"><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:msup><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>E</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mn>6</mml:mn></mml:mfrac></mml:mrow></mml:msup></mml:mrow></mml:math></disp-formula></p><p>where the Förster distance (<italic>R</italic><sub>0</sub>), the distance at which energy transfer is 50% efficient, was determined to be 63 Å (<xref ref-type="bibr" rid="bib19">Fessenden and Yuan, 2009</xref>).</p></sec><sec id="s4-10"><title>Time resolved FRET measurements</title><p>Fluorescence lifetime measurements of M2β 15HPZ.GFP were performed using time-correlated single photon counting (TCSPC; DeltaPro, Horiba Scientific) with a 479 nm pulse diode laser and a 515 nm long-pass emission filter. We examined M2β constructs (60 nM) in the absence of nucleotide, presence of 0.1 µM Cy3ATP, and in the presence of saturating ATP (1 mM) and 0.1 µM Cy3ATP (ATP chase). The myosin samples were equilibrated in the appropriate buffer conditions for 10 min on ice, incubated with or without Cy3ATP for 1 min at room temperature, and measured in TCSPC. The TCSPC measurements took 30–45 s to complete. Then a second TCSPC measurement was taken after the addition of 1 mM ATP (ATP chase). The fluorescence lifetime decays were fit to two-exponential function and used to determine the average lifetime of the donor alone (τ<italic><sub>D</sub></italic>) and donor+acceptor (τ<italic><sub>DA</sub></italic>). The FRET efficiency was calculated using the following equation:<disp-formula id="equ3"><mml:math id="m3"><mml:mrow><mml:mi>E</mml:mi><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mfrac><mml:msub><mml:mi>τ</mml:mi><mml:mrow><mml:mi>D</mml:mi><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>τ</mml:mi><mml:mrow><mml:mi>D</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>Three technical replicates were performed on a single protein preparation, and the average FRET efficiency (± SD) was then used to determine the FRET distance (<italic>r</italic>) as described above.</p></sec><sec id="s4-11"><title>Electron microscopy</title><sec id="s4-11-1"><title>Sample preparation and imaging</title><p>The samples (WT and E525K M2β 15HPZ.GFP) were diluted in 20 mM KCl, 10 mM MOPS, 1 mM EGTA, 0.5 mM ATP, 2 mM MgCl<sub>2</sub>, and pH 7.4 to a final concentration of 77 nM and incubated at room temperature for 10 min. Negative staining was performed using 400 mesh copper grids with a thin carbon film on top. The grids were glow discharged for 45 s at 15 mA in a PELCO easiGlow to make the surface hydrophilic, aiding stain spreading. 5 µl of sample was applied to the grid for ~5 s to minimize disruption of the IHM due to binding to the carbon (<xref ref-type="bibr" rid="bib9">Burgess et al., 2007</xref>), and the grid immediately rinsed with 1% (w/v) uranyl acetate for negative staining. Grids were imaged on a FEI Tecnai Spirit Transmission Electron Microscope at 120 kV with a Rio 9 3K × 3K CCD camera (Gatan). The EM experiments with WT and E525K were repeated in three separate protein preparations, each performed in parallel in order to compare the WT and mutant on grids prepared on the same day under identical conditions.</p></sec><sec id="s4-11-2"><title>Calculation of percentage folded molecules</title><p>A total of 4–9 micrographs (257–318 molecules) for each replicate (three separate protein preparations) of each construct were analyzed, and visual counting was performed to calculate the percent of folded molecules.</p></sec><sec id="s4-11-3"><title>2-D classification and averaging</title><p>A total of 55 micrographs with 2.6 Å pixel size were used to extract 1397 (WT) and 1845 particles (E525K) in Relion 3.1.2 (<xref ref-type="bibr" rid="bib49">Scheres, 2012</xref>). The particles were classified into 50 classes with a mask size of 520 Å, and the top 10 classes were used to make the comparison.</p></sec></sec><sec id="s4-12"><title>Statistics</title><p>For this work, a biological replicate is defined as a new protein preparation, whereas a technical replicate is defined as a repeated experiment from the same stock of protein. Reported sample sizes refer specifically to biological replicates (except where noted), and a minimum of N=3 is reported for all experiments. Groups were allocated as WT vs. E525K or S1 vs. HMM, unless otherwise noted, and direct comparisons were made between these two groups. Accordingly, unpaired Student’s <italic>t</italic>-tests were performed to compare differences between the groups in all experiments with statistical error. To avoid technical replicates in the IVM assay (i.e. actin filaments from the experiment), sample means of independent experiments were averaged, and the data have been presented as SuperPlots, as previously described (<xref ref-type="bibr" rid="bib34">Lord et al., 2020</xref>; <xref ref-type="bibr" rid="bib43">Rasicci et al., 2021</xref>). Stuck filaments (velocity = 0 nm s<sup>−1</sup>) were excluded from this analysis. Otherwise, no data was excluded from any other reported experiment. The p-values for all statistical comparisons can be found in the source files.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Writing – review and editing, Formal analysis, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Data curation, Writing – review and editing, Writing - original draft</p></fn><fn fn-type="con" id="con3"><p>Data curation, Writing - original draft</p></fn><fn fn-type="con" id="con4"><p>Data curation, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con5"><p>Data curation, Writing – review and editing, Writing - original draft</p></fn><fn fn-type="con" id="con6"><p>Writing – review and editing, Supervision, Writing - original draft</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Writing – review and editing, Supervision, Funding acquisition, Writing - original draft</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Data curation, Writing – review and editing, Funding acquisition, Formal analysis, Project administration, Writing - original draft</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media xlink:href="elife-77415-transrepform1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting file; Source Data files have been provided for Figures 2-6.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This work was supported by NIH grants to HL127699 to CMY, HL150953 to CMY and SS, AR072036, HL139883, HL164560 to RC, and an AHA Post-doctoral Fellowship to PT.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adamek</surname><given-names>N</given-names></name><name><surname>Lieto-Trivedi</surname><given-names>A</given-names></name><name><surname>Geeves</surname><given-names>MA</given-names></name><name><surname>Coluccio</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Modification of loop 1 affects the nucleotide binding properties of myo1c, the adaptation motor in the inner ear</article-title><source>Biochemistry</source><volume>49</volume><fpage>958</fpage><lpage>971</lpage><pub-id pub-id-type="doi">10.1021/bi901803j</pub-id><pub-id pub-id-type="pmid">20039646</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adhikari</surname><given-names>AS</given-names></name><name><surname>Trivedi</surname><given-names>DV</given-names></name><name><surname>Sarkar</surname><given-names>SS</given-names></name><name><surname>Song</surname><given-names>D</given-names></name><name><surname>Kooiker</surname><given-names>KB</given-names></name><name><surname>Bernstein</surname><given-names>D</given-names></name><name><surname>Spudich</surname><given-names>JA</given-names></name><name><surname>Ruppel</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Β-Cardiac myosin hypertrophic cardiomyopathy mutations release sequestered heads and increase enzymatic activity</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>2685</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10555-9</pub-id><pub-id pub-id-type="pmid">31213605</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aksel</surname><given-names>T</given-names></name><name><surname>Choe Yu</surname><given-names>E</given-names></name><name><surname>Sutton</surname><given-names>S</given-names></name><name><surname>Ruppel</surname><given-names>KM</given-names></name><name><surname>Spudich</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Ensemble force changes that result from human cardiac myosin mutations and a small-molecule effector</article-title><source>Cell Reports</source><volume>11</volume><fpage>910</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2015.04.006</pub-id><pub-id pub-id-type="pmid">25937279</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alamo</surname><given-names>L</given-names></name><name><surname>Wriggers</surname><given-names>W</given-names></name><name><surname>Pinto</surname><given-names>A</given-names></name><name><surname>Bártoli</surname><given-names>F</given-names></name><name><surname>Salazar</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>F-Q</given-names></name><name><surname>Craig</surname><given-names>R</given-names></name><name><surname>Padrón</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Three-Dimensional reconstruction of tarantula myosin filaments suggests how phosphorylation may regulate myosin activity</article-title><source>Journal of Molecular Biology</source><volume>384</volume><fpage>780</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2008.10.013</pub-id><pub-id pub-id-type="pmid">18951904</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alamo</surname><given-names>L</given-names></name><name><surname>Ware</surname><given-names>JS</given-names></name><name><surname>Pinto</surname><given-names>A</given-names></name><name><surname>Gillilan</surname><given-names>RE</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Padrón</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Effects of myosin variants on interacting-heads motif explain distinct hypertrophic and dilated cardiomyopathy phenotypes</article-title><source>eLife</source><volume>6</volume><elocation-id>e24634</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.24634</pub-id><pub-id pub-id-type="pmid">28606303</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alamo</surname><given-names>L</given-names></name><name><surname>Pinto</surname><given-names>A</given-names></name><name><surname>Sulbarán</surname><given-names>G</given-names></name><name><surname>Mavárez</surname><given-names>J</given-names></name><name><surname>Padrón</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Lessons from a tarantula: new insights into myosin interacting-heads motif evolution and its implications on disease</article-title><source>Biophysical Reviews</source><volume>10</volume><fpage>1465</fpage><lpage>1477</lpage><pub-id pub-id-type="doi">10.1007/s12551-017-0292-4</pub-id><pub-id pub-id-type="pmid">28871552</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>AlKhayat</surname><given-names>HA</given-names></name><name><surname>Kensler</surname><given-names>RW</given-names></name><name><surname>Squire</surname><given-names>JM</given-names></name><name><surname>Marston</surname><given-names>SB</given-names></name><name><surname>Morris</surname><given-names>EP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Atomic model of the human cardiac muscle myosin filament</article-title><source>PNAS</source><volume>110</volume><fpage>318</fpage><lpage>323</lpage><pub-id pub-id-type="doi">10.1073/pnas.1212708110</pub-id><pub-id pub-id-type="pmid">23251030</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>RL</given-names></name><name><surname>Trivedi</surname><given-names>DV</given-names></name><name><surname>Sarkar</surname><given-names>SS</given-names></name><name><surname>Henze</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Gong</surname><given-names>H</given-names></name><name><surname>Rogers</surname><given-names>CS</given-names></name><name><surname>Gorham</surname><given-names>JM</given-names></name><name><surname>Wong</surname><given-names>FL</given-names></name><name><surname>Morck</surname><given-names>MM</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Ruppel</surname><given-names>KM</given-names></name><name><surname>Irving</surname><given-names>TC</given-names></name><name><surname>Cooke</surname><given-names>R</given-names></name><name><surname>Green</surname><given-names>EM</given-names></name><name><surname>Spudich</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Deciphering the super relaxed state of human β-cardiac myosin and the mode of action of mavacamten from myosin molecules to muscle fibers</article-title><source>PNAS</source><volume>115</volume><fpage>E8143</fpage><lpage>E8152</lpage><pub-id pub-id-type="doi">10.1073/pnas.1809540115</pub-id><pub-id pub-id-type="pmid">30104387</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burgess</surname><given-names>SA</given-names></name><name><surname>Yu</surname><given-names>S</given-names></name><name><surname>Walker</surname><given-names>ML</given-names></name><name><surname>Hawkins</surname><given-names>RJ</given-names></name><name><surname>Chalovich</surname><given-names>JM</given-names></name><name><surname>Knight</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Structures of smooth muscle myosin and heavy meromyosin in the folded, shutdown state</article-title><source>Journal of Molecular Biology</source><volume>372</volume><fpage>1165</fpage><lpage>1178</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2007.07.014</pub-id><pub-id pub-id-type="pmid">17707861</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>KS</given-names></name><name><surname>Janssen</surname><given-names>PML</given-names></name><name><surname>Campbell</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Force-Dependent recruitment from the myosin off state contributes to length-dependent activation</article-title><source>Biophysical Journal</source><volume>115</volume><fpage>543</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2018.07.006</pub-id><pub-id pub-id-type="pmid">30054031</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>D</given-names></name><name><surname>Srikakulam</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Winkelmann</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Folding of the striated muscle myosin motor domain</article-title><source>The Journal of Biological Chemistry</source><volume>277</volume><fpage>36799</fpage><lpage>36807</lpage><pub-id pub-id-type="doi">10.1074/jbc.M204101200</pub-id><pub-id pub-id-type="pmid">12110670</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>S</given-names></name><name><surname>Muretta</surname><given-names>JM</given-names></name><name><surname>Thomas</surname><given-names>DD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Direct detection of the myosin super-relaxed state and interacting-heads motif in solution</article-title><source>The Journal of Biological Chemistry</source><volume>297</volume><elocation-id>101157</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2021.101157</pub-id><pub-id pub-id-type="pmid">34481842</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>R</given-names></name><name><surname>Ansari</surname><given-names>MA</given-names></name><name><surname>Dash</surname><given-names>S</given-names></name><name><surname>Geeves</surname><given-names>MA</given-names></name><name><surname>Coluccio</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Loop 1 of transducer region in mammalian class I myosin, Myo1b, modulates actin affinity, ATPase activity, and nucleotide access</article-title><source>The Journal of Biological Chemistry</source><volume>280</volume><fpage>30935</fpage><lpage>30942</lpage><pub-id pub-id-type="doi">10.1074/jbc.M504698200</pub-id><pub-id pub-id-type="pmid">15980431</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colegrave</surname><given-names>M</given-names></name><name><surname>Peckham</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Structural implications of β-cardiac myosin heavy chain mutations in human disease</article-title><source>Anatomical Record</source><volume>297</volume><fpage>1670</fpage><lpage>1680</lpage><pub-id pub-id-type="doi">10.1002/ar.22973</pub-id><pub-id pub-id-type="pmid">25125180</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craig</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Kendrick-Jones</surname><given-names>J</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>Light-chain phosphorylation controls the conformation of vertebrate non-muscle and smooth muscle myosin molecules</article-title><source>Nature</source><volume>302</volume><fpage>436</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1038/302436a0</pub-id><pub-id pub-id-type="pmid">6687627</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Craig</surname><given-names>R</given-names></name><name><surname>Padrón</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Structural basis of the super- and hyper-relaxed states of myosin II</article-title><source>The Journal of General Physiology</source><volume>154</volume><elocation-id>e202113012</elocation-id><pub-id pub-id-type="doi">10.1085/jgp.202113012</pub-id><pub-id pub-id-type="pmid">34889960</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>RA</given-names></name><name><surname>Jackson</surname><given-names>AP</given-names></name><name><surname>Citi</surname><given-names>S</given-names></name><name><surname>Kendrick-Jones</surname><given-names>J</given-names></name><name><surname>Bagshaw</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="1988">1988</year><article-title>Active site trapping of nucleotide by smooth and non-muscle myosins</article-title><source>Journal of Molecular Biology</source><volume>203</volume><fpage>173</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/0022-2836(88)90100-3</pub-id><pub-id pub-id-type="pmid">3054120</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debold</surname><given-names>EP</given-names></name><name><surname>Schmitt</surname><given-names>JP</given-names></name><name><surname>Patlak</surname><given-names>JB</given-names></name><name><surname>Beck</surname><given-names>SE</given-names></name><name><surname>Moore</surname><given-names>JR</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>C</given-names></name><name><surname>Warshaw</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Hypertrophic and dilated cardiomyopathy mutations differentially affect the molecular force generation of mouse α-cardiac myosin in the laser trap assay</article-title><source>American Journal of Physiology-Heart and Circulatory Physiology</source><volume>293</volume><fpage>H284</fpage><lpage>H291</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00128.2007</pub-id><pub-id pub-id-type="pmid">17351073</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fessenden</surname><given-names>JD</given-names></name><name><surname>Yuan</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Förster resonance energy transfer measurements of ryanodine receptor type 1 structure using a novel site-specific labeling method</article-title><source>PLOS ONE</source><volume>4</volume><elocation-id>e7338</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0007338</pub-id><pub-id pub-id-type="pmid">19823671</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geeves</surname><given-names>MA</given-names></name><name><surname>Perreault-Micale</surname><given-names>C</given-names></name><name><surname>Coluccio</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Kinetic analyses of a truncated mammalian myosin I suggest a novel isomerization event preceding nucleotide binding</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>21624</fpage><lpage>21630</lpage><pub-id pub-id-type="doi">10.1074/jbc.M000342200</pub-id><pub-id pub-id-type="pmid">10781577</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gollapudi</surname><given-names>SK</given-names></name><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Gan</surname><given-names>QF</given-names></name><name><surname>Nag</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Synthetic thick filaments: a new avenue for better understanding the myosin super-relaxed state in healthy, diseased, and mavacamten-treated cardiac systems</article-title><source>The Journal of Biological Chemistry</source><volume>296</volume><elocation-id>100114</elocation-id><pub-id pub-id-type="doi">10.1074/jbc.RA120.016506</pub-id><pub-id pub-id-type="pmid">33234590</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gunther</surname><given-names>LK</given-names></name><name><surname>Rohde</surname><given-names>JA</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Walton</surname><given-names>SD</given-names></name><name><surname>Unrath</surname><given-names>WC</given-names></name><name><surname>Trivedi</surname><given-names>DV</given-names></name><name><surname>Muretta</surname><given-names>JM</given-names></name><name><surname>Thomas</surname><given-names>DD</given-names></name><name><surname>Yengo</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Converter domain mutations in myosin alter structural kinetics and motor function</article-title><source>The Journal of Biological Chemistry</source><volume>294</volume><fpage>1554</fpage><lpage>1567</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.006128</pub-id><pub-id pub-id-type="pmid">30518549</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heissler</surname><given-names>SM</given-names></name><name><surname>Arora</surname><given-names>AS</given-names></name><name><surname>Billington</surname><given-names>N</given-names></name><name><surname>Sellers</surname><given-names>JR</given-names></name><name><surname>Chinthalapudi</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cryo-Em structure of the autoinhibited state of myosin-2</article-title><source>Science Advances</source><volume>7</volume><elocation-id>eabk3273</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.abk3273</pub-id><pub-id pub-id-type="pmid">34936462</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>CY</given-names></name><name><surname>Sweitzer</surname><given-names>NK</given-names></name><name><surname>McDonough</surname><given-names>B</given-names></name><name><surname>Maron</surname><given-names>BJ</given-names></name><name><surname>Casey</surname><given-names>SA</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Solomon</surname><given-names>SD</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy</article-title><source>Circulation</source><volume>105</volume><fpage>2992</fpage><lpage>2997</lpage><pub-id pub-id-type="doi">10.1161/01.cir.0000019070.70491.6d</pub-id><pub-id pub-id-type="pmid">12081993</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hooijman</surname><given-names>P</given-names></name><name><surname>Stewart</surname><given-names>MA</given-names></name><name><surname>Cooke</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A new state of cardiac myosin with very slow ATP turnover: a potential cardioprotective mechanism in the heart</article-title><source>Biophysical Journal</source><volume>100</volume><fpage>1969</fpage><lpage>1976</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2011.02.061</pub-id><pub-id pub-id-type="pmid">21504733</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>HS</given-names></name><name><surname>Komatsu</surname><given-names>S</given-names></name><name><surname>Ikebe</surname><given-names>M</given-names></name><name><surname>Craig</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Head-Head and head-tail interaction: a general mechanism for switching off myosin II activity in cells</article-title><source>Molecular Biology of the Cell</source><volume>19</volume><fpage>3234</fpage><lpage>3242</lpage><pub-id pub-id-type="doi">10.1091/mbc.E08-02-0206</pub-id><pub-id pub-id-type="pmid">18495867</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kampourakis</surname><given-names>T</given-names></name><name><surname>Irving</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The regulatory light chain mediates inactivation of myosin motors during active shortening of cardiac muscle</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>5272</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-25601-8</pub-id><pub-id pub-id-type="pmid">34489440</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>T</given-names></name><name><surname>Solaro</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Calcium, thin filaments, and the integrative biology of cardiac contractility</article-title><source>Annual Review of Physiology</source><volume>67</volume><fpage>39</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1146/annurev.physiol.67.040403.114025</pub-id><pub-id pub-id-type="pmid">15709952</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kron</surname><given-names>SJ</given-names></name><name><surname>Toyoshima</surname><given-names>YY</given-names></name><name><surname>Uyeda</surname><given-names>TQ</given-names></name><name><surname>Spudich</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Assays for actin sliding movement over myosin-coated surfaces</article-title><source>Methods in Enzymology</source><volume>196</volume><fpage>399</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1016/0076-6879(91)96035-p</pub-id><pub-id pub-id-type="pmid">2034132</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakdawala</surname><given-names>NK</given-names></name><name><surname>Funke</surname><given-names>BH</given-names></name><name><surname>Baxter</surname><given-names>S</given-names></name><name><surname>Cirino</surname><given-names>AL</given-names></name><name><surname>Roberts</surname><given-names>AE</given-names></name><name><surname>Judge</surname><given-names>DP</given-names></name><name><surname>Johnson</surname><given-names>N</given-names></name><name><surname>Mendelsohn</surname><given-names>NJ</given-names></name><name><surname>Morel</surname><given-names>C</given-names></name><name><surname>Care</surname><given-names>M</given-names></name><name><surname>Chung</surname><given-names>WK</given-names></name><name><surname>Jones</surname><given-names>C</given-names></name><name><surname>Psychogios</surname><given-names>A</given-names></name><name><surname>Duffy</surname><given-names>E</given-names></name><name><surname>Rehm</surname><given-names>HL</given-names></name><name><surname>White</surname><given-names>E</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Ho</surname><given-names>CY</given-names></name></person-group><year iso-8601-date="2012">2012a</year><article-title>Genetic testing for dilated cardiomyopathy in clinical practice</article-title><source>Journal of Cardiac Failure</source><volume>18</volume><fpage>296</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.1016/j.cardfail.2012.01.013</pub-id><pub-id pub-id-type="pmid">22464770</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lakdawala</surname><given-names>NK</given-names></name><name><surname>Thune</surname><given-names>JJ</given-names></name><name><surname>Colan</surname><given-names>SD</given-names></name><name><surname>Cirino</surname><given-names>AL</given-names></name><name><surname>Farrohi</surname><given-names>F</given-names></name><name><surname>Rivero</surname><given-names>J</given-names></name><name><surname>McDonough</surname><given-names>B</given-names></name><name><surname>Sparks</surname><given-names>E</given-names></name><name><surname>Orav</surname><given-names>EJ</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Ho</surname><given-names>CY</given-names></name></person-group><year iso-8601-date="2012">2012b</year><article-title>Subtle abnormalities in contractile function are an early manifestation of sarcomere mutations in dilated cardiomyopathy</article-title><source>Circulation. Cardiovascular Genetics</source><volume>5</volume><fpage>503</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1161/CIRCGENETICS.112.962761</pub-id><pub-id pub-id-type="pmid">22949430</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Lakowicz</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2006">2006</year><source>Principles of Fluorescence Spectroscopy</source><publisher-name>Springer</publisher-name><pub-id pub-id-type="doi">10.1007/978-0-387-46312-4</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Sulbarán</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Mun</surname><given-names>JY</given-names></name><name><surname>Alamo</surname><given-names>L</given-names></name><name><surname>Pinto</surname><given-names>A</given-names></name><name><surname>Sato</surname><given-names>O</given-names></name><name><surname>Ikebe</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Korn</surname><given-names>ED</given-names></name><name><surname>Sarsoza</surname><given-names>F</given-names></name><name><surname>Bernstein</surname><given-names>SI</given-names></name><name><surname>Padrón</surname><given-names>R</given-names></name><name><surname>Craig</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Interacting-heads motif has been conserved as a mechanism of myosin II inhibition since before the origin of animals</article-title><source>PNAS</source><volume>115</volume><fpage>E1991</fpage><lpage>E2000</lpage><pub-id pub-id-type="doi">10.1073/pnas.1715247115</pub-id><pub-id pub-id-type="pmid">29444861</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname><given-names>SJ</given-names></name><name><surname>Velle</surname><given-names>KB</given-names></name><name><surname>Mullins</surname><given-names>RD</given-names></name><name><surname>Fritz-Laylin</surname><given-names>LK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SuperPlots: communicating reproducibility and variability in cell biology</article-title><source>The Journal of Cell Biology</source><volume>219</volume><elocation-id>e202001064</elocation-id><pub-id pub-id-type="doi">10.1083/jcb.202001064</pub-id><pub-id pub-id-type="pmid">32346721</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNally</surname><given-names>EM</given-names></name><name><surname>Mestroni</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Dilated cardiomyopathy: genetic determinants and mechanisms</article-title><source>Circulation Research</source><volume>121</volume><fpage>731</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.309396</pub-id><pub-id pub-id-type="pmid">28912180</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNamara</surname><given-names>JW</given-names></name><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Dos Remedios</surname><given-names>CG</given-names></name><name><surname>Cooke</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The role of super-relaxed myosin in skeletal and cardiac muscle</article-title><source>Biophysical Reviews</source><volume>7</volume><fpage>5</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1007/s12551-014-0151-5</pub-id><pub-id pub-id-type="pmid">28509977</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nag</surname><given-names>S</given-names></name><name><surname>Trivedi</surname><given-names>DV</given-names></name><name><surname>Sarkar</surname><given-names>SS</given-names></name><name><surname>Adhikari</surname><given-names>AS</given-names></name><name><surname>Sunitha</surname><given-names>MS</given-names></name><name><surname>Sutton</surname><given-names>S</given-names></name><name><surname>Ruppel</surname><given-names>KM</given-names></name><name><surname>Spudich</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The myosin MESA and the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>24</volume><fpage>525</fpage><lpage>533</lpage><pub-id pub-id-type="doi">10.1038/nsmb.3408</pub-id><pub-id pub-id-type="pmid">28481356</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nag</surname><given-names>S</given-names></name><name><surname>Trivedi</surname><given-names>DV</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>To lie or not to lie: super-relaxing with myosins</article-title><source>eLife</source><volume>10</volume><elocation-id>e63703</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.63703</pub-id><pub-id pub-id-type="pmid">33565963</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagueh</surname><given-names>SF</given-names></name><name><surname>McFalls</surname><given-names>J</given-names></name><name><surname>Meyer</surname><given-names>D</given-names></name><name><surname>Hill</surname><given-names>R</given-names></name><name><surname>Zoghbi</surname><given-names>WA</given-names></name><name><surname>Tam</surname><given-names>JW</given-names></name><name><surname>Quiñones</surname><given-names>MA</given-names></name><name><surname>Roberts</surname><given-names>R</given-names></name><name><surname>Marian</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease</article-title><source>Circulation</source><volume>108</volume><fpage>395</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000084500.72232.8D</pub-id><pub-id pub-id-type="pmid">12860897</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onishi</surname><given-names>H</given-names></name><name><surname>Wakabayashi</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>Electron microscopic studies of myosin molecules from chicken gizzard muscle I: the formation of the intramolecular loop in the myosin tail</article-title><source>Journal of Biochemistry</source><volume>92</volume><fpage>871</fpage><lpage>879</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.jbchem.a134001</pub-id><pub-id pub-id-type="pmid">7142124</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pardee</surname><given-names>JD</given-names></name><name><surname>Spudich</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>Purification of muscle actin</article-title><source>Methods in Enzymology</source><volume>85 Pt B</volume><fpage>164</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1016/0076-6879(82)85020-9</pub-id><pub-id pub-id-type="pmid">7121269</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pettersen</surname><given-names>EF</given-names></name><name><surname>Goddard</surname><given-names>TD</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Couch</surname><given-names>GS</given-names></name><name><surname>Greenblatt</surname><given-names>DM</given-names></name><name><surname>Meng</surname><given-names>EC</given-names></name><name><surname>Ferrin</surname><given-names>TE</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>UCSF chimera -- a visualization system for exploratory research and analysis</article-title><source>Journal of Computational Chemistry</source><volume>25</volume><fpage>1605</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1002/jcc.20084</pub-id><pub-id pub-id-type="pmid">15264254</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasicci</surname><given-names>DV</given-names></name><name><surname>Kirkland</surname><given-names>O</given-names></name><name><surname>Moonschi</surname><given-names>FH</given-names></name><name><surname>Wood</surname><given-names>NB</given-names></name><name><surname>Szczesna-Cordary</surname><given-names>D</given-names></name><name><surname>Previs</surname><given-names>MJ</given-names></name><name><surname>Wenk</surname><given-names>JF</given-names></name><name><surname>Campbell</surname><given-names>KS</given-names></name><name><surname>Yengo</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Impact of regulatory light chain mutation K104E on the ATPase and motor properties of cardiac myosin</article-title><source>The Journal of General Physiology</source><volume>153</volume><elocation-id>e202012811</elocation-id><pub-id pub-id-type="doi">10.1085/jgp.202012811</pub-id><pub-id pub-id-type="pmid">33891674</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robert-Paganin</surname><given-names>J</given-names></name><name><surname>Auguin</surname><given-names>D</given-names></name><name><surname>Houdusse</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition</article-title><source>Nature Communications</source><volume>9</volume><elocation-id>4019</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-06191-4</pub-id><pub-id pub-id-type="pmid">30275503</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rohde</surname><given-names>JA</given-names></name><name><surname>Roopnarine</surname><given-names>O</given-names></name><name><surname>Thomas</surname><given-names>DD</given-names></name><name><surname>Muretta</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mavacamten stabilizes an autoinhibited state of two-headed cardiac myosin</article-title><source>PNAS</source><volume>115</volume><fpage>E7486</fpage><lpage>E7494</lpage><pub-id pub-id-type="doi">10.1073/pnas.1720342115</pub-id><pub-id pub-id-type="pmid">30018063</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sarkar</surname><given-names>SS</given-names></name><name><surname>Trivedi</surname><given-names>DV</given-names></name><name><surname>Morck</surname><given-names>MM</given-names></name><name><surname>Adhikari</surname><given-names>AS</given-names></name><name><surname>Pasha</surname><given-names>SN</given-names></name><name><surname>Ruppel</surname><given-names>KM</given-names></name><name><surname>Spudich</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The hypertrophic cardiomyopathy mutations R403Q and R663H increase the number of myosin heads available to interact with actin</article-title><source>Science Advances</source><volume>6</volume><elocation-id>eaax0069</elocation-id><pub-id pub-id-type="doi">10.1126/sciadv.aax0069</pub-id><pub-id pub-id-type="pmid">32284968</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scarff</surname><given-names>CA</given-names></name><name><surname>Carrington</surname><given-names>G</given-names></name><name><surname>Casas-Mao</surname><given-names>D</given-names></name><name><surname>Chalovich</surname><given-names>JM</given-names></name><name><surname>Knight</surname><given-names>PJ</given-names></name><name><surname>Ranson</surname><given-names>NA</given-names></name><name><surname>Peckham</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structure of the shutdown state of myosin-2</article-title><source>Nature</source><volume>588</volume><fpage>515</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2990-5</pub-id><pub-id pub-id-type="pmid">33268888</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schafer</surname><given-names>S</given-names></name><name><surname>de Marvao</surname><given-names>A</given-names></name><name><surname>Adami</surname><given-names>E</given-names></name><name><surname>Fiedler</surname><given-names>LR</given-names></name><name><surname>Ng</surname><given-names>B</given-names></name><name><surname>Khin</surname><given-names>E</given-names></name><name><surname>Rackham</surname><given-names>OJL</given-names></name><name><surname>van Heesch</surname><given-names>S</given-names></name><name><surname>Pua</surname><given-names>CJ</given-names></name><name><surname>Kui</surname><given-names>M</given-names></name><name><surname>Walsh</surname><given-names>R</given-names></name><name><surname>Tayal</surname><given-names>U</given-names></name><name><surname>Prasad</surname><given-names>SK</given-names></name><name><surname>Dawes</surname><given-names>TJW</given-names></name><name><surname>Ko</surname><given-names>NSJ</given-names></name><name><surname>Sim</surname><given-names>D</given-names></name><name><surname>Chan</surname><given-names>LLH</given-names></name><name><surname>Chin</surname><given-names>CWL</given-names></name><name><surname>Mazzarotto</surname><given-names>F</given-names></name><name><surname>Barton</surname><given-names>PJ</given-names></name><name><surname>Kreuchwig</surname><given-names>F</given-names></name><name><surname>de Kleijn</surname><given-names>DPV</given-names></name><name><surname>Totman</surname><given-names>T</given-names></name><name><surname>Biffi</surname><given-names>C</given-names></name><name><surname>Tee</surname><given-names>N</given-names></name><name><surname>Rueckert</surname><given-names>D</given-names></name><name><surname>Schneider</surname><given-names>V</given-names></name><name><surname>Faber</surname><given-names>A</given-names></name><name><surname>Regitz-Zagrosek</surname><given-names>V</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Linke</surname><given-names>WA</given-names></name><name><surname>Kovalik</surname><given-names>J-P</given-names></name><name><surname>O’Regan</surname><given-names>D</given-names></name><name><surname>Ware</surname><given-names>JS</given-names></name><name><surname>Hubner</surname><given-names>N</given-names></name><name><surname>Cook</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Titin-truncating variants affect heart function in disease cohorts and the general population</article-title><source>Nature Genetics</source><volume>49</volume><fpage>46</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1038/ng.3719</pub-id><pub-id pub-id-type="pmid">27869827</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheres</surname><given-names>SHW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>RELION: implementation of a Bayesian approach to cryo-EM structure determination</article-title><source>Journal of Structural Biology</source><volume>180</volume><fpage>519</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1016/j.jsb.2012.09.006</pub-id><pub-id pub-id-type="pmid">23000701</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spudich</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases</article-title><source>Biophysical Journal</source><volume>106</volume><fpage>1236</fpage><lpage>1249</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2014.02.011</pub-id><pub-id pub-id-type="pmid">24655499</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spudich</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The myosin MESA and a possible unifying hypothesis for the molecular basis of human hypertrophic cardiomyopathy</article-title><source>Biochemical Society Transactions</source><volume>43</volume><fpage>64</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1042/BST20140324</pub-id><pub-id pub-id-type="pmid">25619247</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>MA</given-names></name><name><surname>Franks-Skiba</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Cooke</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Myosin ATP turnover rate is a mechanism involved in thermogenesis in resting skeletal muscle fibers</article-title><source>PNAS</source><volume>107</volume><fpage>430</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1073/pnas.0909468107</pub-id><pub-id pub-id-type="pmid">19966283</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swenson</surname><given-names>AM</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Blair</surname><given-names>CA</given-names></name><name><surname>Fetrow</surname><given-names>CM</given-names></name><name><surname>Unrath</surname><given-names>WC</given-names></name><name><surname>Previs</surname><given-names>MJ</given-names></name><name><surname>Campbell</surname><given-names>KS</given-names></name><name><surname>Yengo</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Omecamtiv mecarbil enhances the duty ratio of human β-cardiac myosin resulting in increased calcium sensitivity and slowed force development in cardiac muscle</article-title><source>The Journal of Biological Chemistry</source><volume>292</volume><fpage>3768</fpage><lpage>3778</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.748780</pub-id><pub-id pub-id-type="pmid">28082673</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Unrath</surname><given-names>WC</given-names></name><name><surname>Desetty</surname><given-names>R</given-names></name><name><surname>Yengo</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cardiomyopathy mutations impact the actin-activated power stroke of human cardiac myosin</article-title><source>Biophysical Journal</source><volume>120</volume><fpage>2222</fpage><lpage>2236</lpage><pub-id pub-id-type="doi">10.1016/j.bpj.2021.04.007</pub-id><pub-id pub-id-type="pmid">33864791</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toepfer</surname><given-names>CN</given-names></name><name><surname>Garfinkel</surname><given-names>AC</given-names></name><name><surname>Venturini</surname><given-names>G</given-names></name><name><surname>Wakimoto</surname><given-names>H</given-names></name><name><surname>Repetti</surname><given-names>G</given-names></name><name><surname>Alamo</surname><given-names>L</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Agarwal</surname><given-names>R</given-names></name><name><surname>Ewoldt</surname><given-names>JF</given-names></name><name><surname>Cloonan</surname><given-names>P</given-names></name><name><surname>Letendre</surname><given-names>J</given-names></name><name><surname>Lun</surname><given-names>M</given-names></name><name><surname>Olivotto</surname><given-names>I</given-names></name><name><surname>Colan</surname><given-names>S</given-names></name><name><surname>Ashley</surname><given-names>E</given-names></name><name><surname>Jacoby</surname><given-names>D</given-names></name><name><surname>Michels</surname><given-names>M</given-names></name><name><surname>Redwood</surname><given-names>CS</given-names></name><name><surname>Watkins</surname><given-names>HC</given-names></name><name><surname>Day</surname><given-names>SM</given-names></name><name><surname>Staples</surname><given-names>JF</given-names></name><name><surname>Padrón</surname><given-names>R</given-names></name><name><surname>Chopra</surname><given-names>A</given-names></name><name><surname>Ho</surname><given-names>CY</given-names></name><name><surname>Chen</surname><given-names>CS</given-names></name><name><surname>Pereira</surname><given-names>AC</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, Informing the pathogenesis of hypertrophic cardiomyopathy</article-title><source>Circulation</source><volume>141</volume><fpage>828</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.042339</pub-id><pub-id pub-id-type="pmid">31983222</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trivedi</surname><given-names>DV</given-names></name><name><surname>Adhikari</surname><given-names>AS</given-names></name><name><surname>Sarkar</surname><given-names>SS</given-names></name><name><surname>Ruppel</surname><given-names>KM</given-names></name><name><surname>Spudich</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Hypertrophic cardiomyopathy and the myosin MESA: viewing an old disease in a new light</article-title><source>Biophysical Reviews</source><volume>10</volume><fpage>27</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1007/s12551-017-0274-6</pub-id><pub-id pub-id-type="pmid">28717924</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trivedi</surname><given-names>DV</given-names></name><name><surname>Nag</surname><given-names>S</given-names></name><name><surname>Spudich</surname><given-names>A</given-names></name><name><surname>Ruppel</surname><given-names>KM</given-names></name><name><surname>Spudich</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The myosin family of mechanoenzymes: from mechanisms to therapeutic approaches</article-title><source>Annual Review of Biochemistry</source><volume>89</volume><fpage>667</fpage><lpage>693</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-011520-105234</pub-id><pub-id pub-id-type="pmid">32169021</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trybus</surname><given-names>KM</given-names></name><name><surname>Huiatt</surname><given-names>TW</given-names></name><name><surname>Lowey</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>A bent monomeric conformation of myosin from smooth muscle</article-title><source>PNAS</source><volume>79</volume><fpage>6151</fpage><lpage>6155</lpage><pub-id pub-id-type="doi">10.1073/pnas.79.20.6151</pub-id><pub-id pub-id-type="pmid">6959106</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trybus</surname><given-names>KM</given-names></name><name><surname>Lowey</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1984">1984</year><article-title>Conformational states of smooth muscle myosin: effects of light chain phosphorylation and ionic strength</article-title><source>The Journal of Biological Chemistry</source><volume>259</volume><fpage>8564</fpage><lpage>8571</lpage><pub-id pub-id-type="pmid">6610679</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trybus</surname><given-names>KM</given-names></name><name><surname>Freyzon</surname><given-names>Y</given-names></name><name><surname>Faust</surname><given-names>LZ</given-names></name><name><surname>Sweeney</surname><given-names>HL</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Spare the rod, spoil the regulation: necessity for a myosin rod</article-title><source>PNAS</source><volume>94</volume><fpage>48</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.1.48</pub-id><pub-id pub-id-type="pmid">8990159</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trybus</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Biochemical studies of myosin</article-title><source>Methods</source><volume>22</volume><fpage>327</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1006/meth.2000.1085</pub-id><pub-id pub-id-type="pmid">11133239</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ujfalusi</surname><given-names>Z</given-names></name><name><surname>Vera</surname><given-names>CD</given-names></name><name><surname>Mijailovich</surname><given-names>SM</given-names></name><name><surname>Svicevic</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>EC</given-names></name><name><surname>Kawana</surname><given-names>M</given-names></name><name><surname>Ruppel</surname><given-names>KM</given-names></name><name><surname>Spudich</surname><given-names>JA</given-names></name><name><surname>Geeves</surname><given-names>MA</given-names></name><name><surname>Leinwand</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Dilated cardiomyopathy myosin mutants have reduced force-generating capacity</article-title><source>The Journal of Biological Chemistry</source><volume>293</volume><fpage>9017</fpage><lpage>9029</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.001938</pub-id><pub-id pub-id-type="pmid">29666183</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ušaj</surname><given-names>M</given-names></name><name><surname>Henn</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Kinetic adaptation of human myo19 for active mitochondrial transport to growing filopodia tips</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>11596</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-11984-6</pub-id><pub-id pub-id-type="pmid">28912602</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vander Roest</surname><given-names>AS</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Morck</surname><given-names>MM</given-names></name><name><surname>Kooiker</surname><given-names>KB</given-names></name><name><surname>Jung</surname><given-names>G</given-names></name><name><surname>Song</surname><given-names>D</given-names></name><name><surname>Dawood</surname><given-names>A</given-names></name><name><surname>Jhingran</surname><given-names>A</given-names></name><name><surname>Pardon</surname><given-names>G</given-names></name><name><surname>Ranjbarvaziri</surname><given-names>S</given-names></name><name><surname>Fajardo</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Campbell</surname><given-names>KS</given-names></name><name><surname>Pruitt</surname><given-names>BL</given-names></name><name><surname>Spudich</surname><given-names>JA</given-names></name><name><surname>Ruppel</surname><given-names>KM</given-names></name><name><surname>Bernstein</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Hypertrophic cardiomyopathy β-cardiac myosin mutation (P710R) leads to hypercontractility by disrupting super relaxed state</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2025030118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2025030118</pub-id><pub-id pub-id-type="pmid">34117120</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Várkuti</surname><given-names>BH</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Kintses</surname><given-names>B</given-names></name><name><surname>Erdélyi</surname><given-names>P</given-names></name><name><surname>Bárdos-Nagy</surname><given-names>I</given-names></name><name><surname>Kovács</surname><given-names>AL</given-names></name><name><surname>Hári</surname><given-names>P</given-names></name><name><surname>Kellermayer</surname><given-names>M</given-names></name><name><surname>Vellai</surname><given-names>T</given-names></name><name><surname>Málnási-Csizmadia</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A novel actin binding site of myosin required for effective muscle contraction</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>19</volume><fpage>299</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2216</pub-id><pub-id pub-id-type="pmid">22343723</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walklate</surname><given-names>J</given-names></name><name><surname>Kao</surname><given-names>K</given-names></name><name><surname>Regnier</surname><given-names>M</given-names></name><name><surname>Geeves</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Exploring the super-relaxed state of myosin in myofibrils from fast-twitch, slow-twitch, and cardiac muscle</article-title><source>The Journal of Biological Chemistry</source><volume>298</volume><elocation-id>101640</elocation-id><pub-id pub-id-type="doi">10.1016/j.jbc.2022.101640</pub-id><pub-id pub-id-type="pmid">35090895</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Moncman</surname><given-names>CL</given-names></name><name><surname>Winkelmann</surname><given-names>DA</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Mutations in the motor domain modulate myosin activity and myofibril organization</article-title><source>Journal of Cell Science</source><volume>116</volume><fpage>4227</fpage><lpage>4238</lpage><pub-id pub-id-type="doi">10.1242/jcs.00709</pub-id><pub-id pub-id-type="pmid">12953063</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wendt</surname><given-names>T</given-names></name><name><surname>Taylor</surname><given-names>D</given-names></name><name><surname>Messier</surname><given-names>T</given-names></name><name><surname>Trybus</surname><given-names>KM</given-names></name><name><surname>Taylor</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Visualization of head-head interactions in the inhibited state of smooth muscle myosin</article-title><source>The Journal of Cell Biology</source><volume>147</volume><fpage>1385</fpage><lpage>1390</lpage><pub-id pub-id-type="doi">10.1083/jcb.147.7.1385</pub-id><pub-id pub-id-type="pmid">10613897</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wendt</surname><given-names>T</given-names></name><name><surname>Taylor</surname><given-names>D</given-names></name><name><surname>Trybus</surname><given-names>KM</given-names></name><name><surname>Taylor</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Three-dimensional image reconstruction of dephosphorylated smooth muscle heavy meromyosin reveals asymmetry in the interaction between myosin heads and placement of subfragment 2</article-title><source>PNAS</source><volume>98</volume><fpage>4361</fpage><lpage>4366</lpage><pub-id pub-id-type="doi">10.1073/pnas.071051098</pub-id><pub-id pub-id-type="pmid">11287639</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winkelmann</surname><given-names>DA</given-names></name><name><surname>Forgacs</surname><given-names>E</given-names></name><name><surname>Miller</surname><given-names>MT</given-names></name><name><surname>Stock</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Structural basis for drug-induced allosteric changes to human β-cardiac myosin motor activity</article-title><source>Nature Communications</source><volume>6</volume><elocation-id>7974</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms8974</pub-id><pub-id pub-id-type="pmid">26246073</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodhead</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>FQ</given-names></name><name><surname>Craig</surname><given-names>R</given-names></name><name><surname>Egelman</surname><given-names>EH</given-names></name><name><surname>Alamo</surname><given-names>L</given-names></name><name><surname>Padrón</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Atomic model of a myosin filament in the relaxed state</article-title><source>Nature</source><volume>436</volume><fpage>1195</fpage><lpage>1199</lpage><pub-id pub-id-type="doi">10.1038/nature03920</pub-id><pub-id pub-id-type="pmid">16121187</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woodhead</surname><given-names>JL</given-names></name><name><surname>Craig</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The MESA TRAIL and the interacting heads motif of myosin II</article-title><source>Archives of Biochemistry and Biophysics</source><volume>680</volume><elocation-id>108228</elocation-id><pub-id pub-id-type="doi">10.1016/j.abb.2019.108228</pub-id><pub-id pub-id-type="pmid">31843643</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Woodhead</surname><given-names>JL</given-names></name><name><surname>Zhao</surname><given-names>F-Q</given-names></name><name><surname>Sulbarán</surname><given-names>G</given-names></name><name><surname>Craig</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>An approach to improve the resolution of helical filaments with a large axial rise and flexible subunits</article-title><source>Journal of Structural Biology</source><volume>193</volume><fpage>45</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.jsb.2015.11.007</pub-id><pub-id pub-id-type="pmid">26592473</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Tiwari</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Sato</surname><given-names>O</given-names></name><name><surname>Ikebe</surname><given-names>M</given-names></name><name><surname>Padrón</surname><given-names>R</given-names></name><name><surname>Craig</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Cryo-Em structure of the inhibited (10S) form of myosin II</article-title><source>Nature</source><volume>588</volume><fpage>521</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-3007-0</pub-id><pub-id pub-id-type="pmid">33268893</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yotti</surname><given-names>R</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Advances in the genetic basis and pathogenesis of sarcomere cardiomyopathies</article-title><source>Annual Review of Genomics and Human Genetics</source><volume>20</volume><fpage>129</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1146/annurev-genom-083118-015306</pub-id><pub-id pub-id-type="pmid">30978303</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>CC</given-names></name><name><surname>Kazmierczak</surname><given-names>K</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Irving</surname><given-names>TC</given-names></name><name><surname>Szczesna-Cordary</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Molecular basis of force-pca relation in MYL2 cardiomyopathy mice: role of the super-relaxed state of myosin</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2110328119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2110328119</pub-id><pub-id pub-id-type="pmid">35177471</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Kampourakis</surname><given-names>T</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Sevrieva</surname><given-names>I</given-names></name><name><surname>Irving</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>YB</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Distinct contributions of the thin and thick filaments to length-dependent activation in heart muscle</article-title><source>eLife</source><volume>6</volume><elocation-id>e24081</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.24081</pub-id><pub-id pub-id-type="pmid">28229860</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>FQ</given-names></name><name><surname>Craig</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Capturing time-resolved changes in molecular structure by negative staining</article-title><source>Journal of Structural Biology</source><volume>141</volume><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/s1047-8477(02)00546-4</pub-id><pub-id pub-id-type="pmid">12576019</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zoghbi</surname><given-names>ME</given-names></name><name><surname>Woodhead</surname><given-names>JL</given-names></name><name><surname>Moss</surname><given-names>RL</given-names></name><name><surname>Craig</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Three-dimensional structure of vertebrate cardiac muscle myosin filaments</article-title><source>PNAS</source><volume>105</volume><fpage>2386</fpage><lpage>2390</lpage><pub-id pub-id-type="doi">10.1073/pnas.0708912105</pub-id><pub-id pub-id-type="pmid">18252826</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.77415.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sellers</surname><given-names>James R</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>National Heart, Lung and Blood Institute, National Institutes of Health</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.02.18.480995" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.02.18.480995"/></front-stub><body><p>This fundamental study demonstrates that a point mutation resulting in dilated cardiomyopathy in human cardiac myosin increases the fraction of molecules that adopt the auto-inhibited super-relaxed conformation. This provides a mechanism for the lower force output observed in the hearts of affected individuals. The data supporting this, utilizing kinetic methods, a FRET-biosensor to detect conformational changes, and electron microscopy are convincing.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.77415.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Sellers</surname><given-names>James R</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01cwqze88</institution-id><institution>National Heart, Lung and Blood Institute, National Institutes of Health</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Ruppel</surname><given-names>Kathleen M</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f54p054</institution-id><institution>Stanford University School of Medicine</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.02.18.480995">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.02.18.480995v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Dilated cardiomyopathy mutation E525K in human β-cardiac myosin stabilizes the interacting heads motif and super-relaxed state of myosin&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Anna Akhmanova as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Kathleen M Ruppel (Reviewer #2).</p><p>Your manuscript has been reviewed by two expert referees and examined by myself. We all found the study timely and of great potential interest. However, both referees had substantial questions that must be addressed.</p><p>Essential revisions:</p><p>Referee #2 and myself were concerned about the low activity and poor quality of the movement of the 15 heptad construct. To rule out a substantial population of dead myosins, you should examine the high salt ATPase activity (K<sup>+</sup>ATPase). In addition, this reviewer also felt that you should do some characterization of the S1 construct bearing the mutation. Reviewer #1 felt that you did not deal sufficiently well with three published papers (Anderson 2018, Rohde 2018 and Chu 2021). All of us were concerned that the different techniques reported different ratios of SRX:DRX states (assuming that these correspond to the folded:unfolded conformations). I had a concern about Figure 4. I presume that the molecules are in the open conformation before the addition of the Cy3ATP. Given the magnitude of the highest rate constants that are measured in Figure 4 at 2.5 μm Cy3ATP, the folding must be fast if the data in E and F are reporting the rate of Cy3ATP binding and not the rate of folding. Again, fits, residuals and more information on the replications, etc are merited here. For example, what [Cy3ATP] was used in A and B? It must be the lowest values used looking at the amplitudes in A compared to the range of amplitudes in the higher nucleotide concentration ranges. What do the traces look like at high nucleotide where the rates should be much faster?</p><p>I am also appending the two reviews verbatim since each referee has numerous points for you to address.</p><p><italic>Reviewer 1 (Recommendations for the authors):</italic></p><p>1. There are no fluorescence spectra showing energy transfer.</p><p>2. It would be helpful to provide expected FRET distances for this pair.</p><p>3. In all cases where single and bi-exponentials are used it would be good to see the fits and residuals (supplementary would be fine).</p><p>4. Figure 4: I was very confused about what this assay was telling us, the fact you see a slower second-order binding constant would imply that the molecules are in the SRX/DRX combinations before nucleotide is applied, which would suggest that nucleotide-free myosin is in the IHM state. To my knowledge, IHM is stabilized by ADP.Pi and wouldn't exist without nucleotide. If the argument is that the signal follows the folding then that should occur at the rate constant for hydrolysis.</p><p>In addition, please explain why amplitudes of the whole combined transients are plotted instead of the individual processes. My thoughts would be that the two separate processes could have different affinities and therefore they should be plotted separately. Also, how well can the slow rate constants be determined with only a 30s acquisition? What are the errors and how many repeats have been made for these observations? These error values should be in the figure legend.</p><p>5. The discussion on using FRET (page 6 second to the last paragraph) was confusing (for me). The fluorescence lifetimes measured were stated to not have consistency, but then these values were used in Figure 5D to claim E525K was more folded than WT at higher salt. I wondered if the two lifetimes could actually represent the dynamics of an SRX-DRX transition? How would that pan out on the timescale of the experiment performed? How long were the samples incubated before measurement? And therefore, how much ATP was hydrolyzed?</p><p>6. Negative stain section (last paragraph page 6): What are the errors on these percentage values? How many repeats?</p><p>7. This statement: &quot;The clinical significance of this study is that DCM mutations can stabilize the auto-inhibited state of myosin, providing a mechanistic basis for the reduced muscle force and power observed in DCM patients&quot; seems to be an over-stretch from the results of a single mutation. The discussion has a more balanced view of this, stating that many DCM mutations affect other processes and DCM literature is less certain about the reduced activity argument.</p><p>8. Last section before the summary and future directions: Surely the fact that nearly 100% of HMM forms SRX at 20 mM KCl should suggest that the signal there represents a fully IHM molecule if the hypothesis is correct. The use of mava would also help here, mava is known to both slow down the ATPase and also allow the formation of IHM. There are conditions, where mava will push nearly everything into the SRX, if you don't see further formation of the FRET sensed IHM then that would suggest this isn't a great IHM sensor. Following the work of Anderson would really help here. They saw approx. 50% SRX without mava that went up to 100% at 25 mM Kac.</p><p><italic>Reviewer 2 (Recommendations for the authors):</italic></p><p>1. The author's claim that E525K myosin has a lower kcat value is based on ATPase data from 15-<italic>hep</italic> constructs which have unusually low activity and extremely high KATPase values (higher than the highest actin concentration used to generate these curves for WT protein). These not only raise doubts about the quality of the protein but will also result in erroneous extrapolated values. The authors should ideally use the S1 constructs to compare kcat values, they already have the viruses for those proteins. The authors should also provide gel images of the purified 15 <italic>hep</italic> proteins showing the three polypeptide chains.</p><p>2. It is not clear, and the authors do not discuss, what the fast and slow phases in the Cy3ATP-binding experiments correspond to. WT and E525K proteins have dramatically different proportions (65% vs. 25% of Afast respectively) of the two phases at low salt- a condition where they have similar SRX (STO assays) and IHM (FRET efficiency) proportions. What is the salt dependence of the rates and proportions of these two phases for WT and E525K proteins? It may help the authors to speculate about the origin of these two phases. It appears from panel 4B that these rates are different for E525K at low vs. high salt, but the authors don't comment on that.</p><p>3. The authors should discuss the limitation in the revised manuscript that the R0 value of the FRET pair used here doesn't allow precise measurement of the distances being probed here to be made and refrain from converting FRET efficiency values to distances.</p><p>4. While it is great that the FRET efficiency values calculated from TR-FRET analysis agree well with the values obtained from Cy3ATP binding experiments at low and high salt, it is not ideal to generate a salt-dependence of the FRET efficiency from TR-FRET experiments from just two data-points as shown in Figure 5D. It may be better to present that data as a comparison within 5A itself without drawing a line through them.</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><p>Thank you for resubmitting your work entitled &quot;Dilated cardiomyopathy mutation E525K in human β-cardiac myosin stabilizes the interacting heads motif and super-relaxed state of myosin&quot; for further consideration by <italic>eLife</italic>. Your revised article has been evaluated by both of the original reviewers, Anna Akhmanova (Senior Editor) and a Reviewing Editor.</p><p>Both the original reviewers and the reviewing editor have read your rebuttal statement and the revised manuscript. All agree that it is much improved although there are still a few points that they would like you to consider. The main concern deals with the idea of 2 different apo-state 15HPZ populations ('open' and 'alt') that differ with respect to their ATP binding affinity. There are some cases in the myosin literature where two exponential nucleotide binding transients have been detected for various myosins, and often the idea of a slow equilibrium between a competent and an incompetent conformation of the myosins has been proposed as opposed to two static populations with inherently different binding rates (See Geeves et al. JBC 275:21624, 2000 for example). Have you considered this? The other concern is that ATP binding to apo-β-cardiac HMM has been reported in the literature to be fit to a single exponential using different experimental set-ups/detection methods:</p><p>a. Bovine cardiac HMM: Rohde et al. 2015, (doi: 10.1073/pnas.1514859112)</p><p>(TR)2 FRET, donor fluorophore is on the RLC, acceptor fluorophore Cy3-ATP</p><p>These authors report that &quot;Cy3-ATP binding to labeled HMM induces a single-exponential time-dependent change in the total fluorescence of the Alexa Fluor donor, consistent with Cy3-ATP binding and formation of a high-FRET state.&quot; (Here the high FRET state is the pre-power stroke state.) Performed under low salt conditions.</p><p>b. Porcine cardiac HMM: Liu et al. (https://doi.org/10.1021/bi5015166)</p><p>Monitored intrinsic tryptophan fluorescence of porcine ventricular HMM at 25 mM KCl upon binding of ATP- data was fitted to a single exponential.</p><p>We realize your readout is different (at least in terms of the position of the donor fluorophore compared with Rohde), and that they are using human protein, but it still seems unlikely that these published studies would see no evidence of two populations under experimental conditions (WT, 20mM KCl) where you see Afast/Aslow of 65%/35%. Also, you are hypothesizing that the population with the decreased binding affinity may represent the IHM state, but then wouldn't you expect to have a smaller Afast for the E525K mutant at 150 mM KCl than WT given your other data?</p><p>Given these literature results, we think it is reasonable to ask that you examine the binding of Cy3ATP to the myosin constructs directly to complement the FRET experiments. Based on your new model you would expect to see a bi-exponential rate process.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.77415.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>Referee #2 and myself were concerned about the low activity and poor quality of the movement of the 15 heptad construct. To rule out a substantial population of dead myosins, you should examine the high salt ATPase activity (K<sup>+</sup>ATPase).</p></disp-quote><p>We have performed NH<sub>4</sub><sup>+</sup> ATPase assays to demonstrate the number of active heads in our myosin preparations (Results-page 4, Methods – pages 11-12). We found that the high-salt ATPase activity was similar in S1 and 15HPZ.GFP demonstrating the 15HPZ.GFP construct does not disrupt folding of the myosin motor domain and that the number of active heads is similar in both preparations. We did find that the E525K mutation increased the high-salt ATPase 20% compared to WT in both the single and double-headed construct.</p><disp-quote content-type="editor-comment"><p>In addition, this reviewer also felt that you should do some characterization of the S1 construct bearing the mutation.</p></disp-quote><p>We now report the steady-state ATPase activity for the E525K M2β S1 construct (Page 4 and Figure 2). We demonstrate, surprisingly, that this mutation enhances actin-activated ATPase activity by increasing the k<sub>cat</sub> and reducing the K<sub>ATPase</sub>. We feel the E525K S1 results are extremely interesting since they demonstrate that the mutation is capable of stabilizing the SRX state even though the motor domain has enhanced intrinsic ATPase activity (see discussion on page 10). We did not perform in vitro motility with the E525K S1 construct since we felt this was another question that is tangential to the main focus of the current paper. Mainly, the question of how E525K specifically alters the intrinsic motor and ATPase activity will be reported in a separate paper that can provide mechanistic details on how the mutation alters myosin motor domain function.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 felt that you did not deal sufficiently well with three published papers (Anderson 2018, Rohde 2018 and Chu 2021).</p></disp-quote><p>We have enhanced our discussion of the Anderson, Rohde, and Chu papers in the discussion (see page 8).</p><disp-quote content-type="editor-comment"><p>All of us were concerned that the different techniques reported different ratios of SRX:DRX states (assuming that these correspond to the folded:unfolded conformations).</p></disp-quote><p>The results of the single turnover and IHM FRET are fairly consistent in terms of the KCl dependance of the SRX:DRX and IHM:Open ratios (pages 4-6 and Figures 3&amp;5). We agree that the EM, although it follows the same trend as the single turnover and FRET, has quite different fractions in the IHM than we observe in solution. We have discussed that this is likely caused by the interaction of the HMM with the EM grid surface, which disrupts the IHM conformation (see pages 6-7). To further address the question of the degree of variability in the EM experiments we have compared three separate preparations and examined the fractional amounts of IHM and open conformations in the WT and mutant (pages 6-7, Figure 6). We suggest surface interactions are known to affect protein conformation and are common in approaches that require attaching a protein to a surface (e.g. EM, AFM). We attempted to minimize these effects by minimizing the contact time of HMM with the grid before staining.</p><disp-quote content-type="editor-comment"><p>I had a concern about Figure 4. I presume that the molecules are in the open conformation before the addition of the Cy3ATP. Given the magnitude of the highest rate constants that are measured in Figure 4 at 2.5 μm Cy3ATP, the folding must be fast if the data in E and F are reporting the rate of Cy3ATP binding and not the rate of folding. Again, fits, residuals and more information on the replications, etc are merited here. For example, what [Cy3ATP] was used in A and B? It must be the lowest values used looking at the amplitudes in A compared to the range of amplitudes in the higher nucleotide concentration ranges. What do the traces look like at high nucleotide where the rates should be much faster?</p></disp-quote><p>We have added more detail to Figure 4. We now include the residuals of the fits in panels A and B. We added the concentration of Cy3ATP (1 µM) and M2β (0.25 µM) to the figure legend. We updated panels A and B by labelling the y-axis to fluorescence, instead of normalized fluorescence. We believe this generated confusion in the previous figure when comparing the y-axis in panels A and B with amplitudes in panels C and D. We did use 1 µM Cy3ATP final for these experiments which is a concentration that achieved saturation of the FRET amplitude (see panels C and D).</p><p>As requested by the reviewers, we enhanced the discussion of the Cy3ATP binding rate constants (page 5 and Figure 4—figure supplements 3 and 4). We agree that the folding into the IHM is relatively rapid following Cy3ATP binding. We have fit the fluorescence transients to a kinetic scheme in which ATP binding is followed by a transition into the IHM, which is rate-limited by the rate of ATP binding under the conditions of our experiments. We also find that since both the fast phase and the slow phase are dependent on ATP concentration, our data fits best to two conformations of myosin in the absence of nucleotide. We propose that one conformation is the open conformation, which binds ATP similar to single headed S1, and the second conformation is an alternative conformation that binds ATP more slowly. We speculate that the alternative conformation could be the IHM or another conformation of the motor domain, however further study is necessary to examine this question (see Discussion page 9).</p><disp-quote content-type="editor-comment"><p>Reviewer 1 (Recommendations for the authors):</p><p>1. There are no fluorescence spectra showing energy transfer.</p></disp-quote><p>We added a figure demonstrating the fluorescence spectra of the donor in the presence and absence of acceptor (see Figure 4—figure supplement 1).</p><disp-quote content-type="editor-comment"><p>2. It would be helpful to provide expected FRET distances for this pair.</p></disp-quote><p>We provide the expected FRET distances in Figure 1 and in page 3 of the results.</p><disp-quote content-type="editor-comment"><p>3. In all cases where single and bi-exponentials are used it would be good to see the fits and residuals (supplementary would be fine).</p></disp-quote><p>See fits and residuals now for all Figures (Figure 3—figure supplements 1 and 2; Figure 4, Figure 5—figure supplement 1).</p><disp-quote content-type="editor-comment"><p>4. Figure 4: I was very confused about what this assay was telling us, the fact you see a slower second-order binding constant would imply that the molecules are in the SRX/DRX combinations before nucleotide is applied, which would suggest that nucleotide-free myosin is in the IHM state. To my knowledge, IHM is stabilized by ADP.Pi and wouldn't exist without nucleotide. If the argument is that the signal follows the folding then that should occur at the rate constant for hydrolysis.</p></disp-quote><p>Our model suggests there are two conformations of nucleotide-free HMM before mixing with Cy3ATP, which gives rise to the fast and slow ATP concentration-dependent rate constants. We suggest the fast rate constant, which is similar to S1, is the open state and the slow component is an alternate conformation. Our model also suggests that the folding occurs fast relative to the ATP binding step. It is true that the alternate conformation could be the IHM even though previous work predicts that the IHM would only form after ATP binding and hydrolysis. Therefore, we suggest further study is necessary to examine the possibility that the IHM may form in nucleotide-free conditions (see pages 5, 8-9).</p><disp-quote content-type="editor-comment"><p>In addition, please explain why amplitudes of the whole combined transients are plotted instead of the individual processes. My thoughts would be that the two separate processes could have different affinities and therefore they should be plotted separately. Also, how well can the slow rate constants be determined with only a 30s acquisition? What are the errors and how many repeats have been made for these observations? These error values should be in the figure legend.</p></disp-quote><p>The amplitudes of the slow and fast components were combined to obtain the overall formation of the IHM conformation in low and high salt conditions. We feel total amplitude is the most informative in comparing the low and high salt conditions. We now also report the amplitudes of both phases in low salt and high salt conditions (see Figure 4—figure supplement 2). We added that each data point represents 3 repetitions from 1 preparation and the errors represent standard error of the fit. A summary of the rate constants and errors is given in Table 4.</p><disp-quote content-type="editor-comment"><p>5. The discussion on using FRET (page 6 second to the last paragraph) was confusing (for me). The fluorescence lifetimes measured were stated to not have consistency, but then these values were used in Figure 5D to claim E525K was more folded than WT at higher salt. I wondered if the two lifetimes could actually represent the dynamics of an SRX-DRX transition? How would that pan out on the timescale of the experiment performed? How long were the samples incubated before measurement? And therefore, how much ATP was hydrolyzed?</p></disp-quote><p>We removed the confusing statement about consistent differences in the short and long components of the lifetime decay, since this comment is relevant to distance distribution analysis which was not performed in this study. The myosin samples were equilibrated in the appropriate buffer conditions for 10 minutes on ice, incubated with Cy3ATP for one minute at room temperature, and measured by TCSPC. The TCSPC measurements were performed within a 30-45 second period (see Methods, page 13). We estimate that most of the myosin would be in the ADP.Pi state during the measurements.</p><p>Since the lifetimes are on a nanosecond timescale any structural changes on the millisecond and microsecond timescale can be observed by performing transient time resolved FRET (TR2-FRET), which requires specialized instrumentation. In the equilibrium experiments performed in this study we assume there is a distribution of open and IHM structural states and our results will be an ensemble average of the structural states populated in solution.</p><disp-quote content-type="editor-comment"><p>6. Negative stain section (last paragraph page 6): What are the errors on these percentage values? How many repeats?</p></disp-quote><p>We performed EM experiments on a total of 3 different preparations of WT and E525K enabling us to make 3 side-by-side comparisons with identical grid conditions in each case. We updated Figure 6 (pages 6-7) to demonstrate the similar trend in the data in all 3 preparations, in terms of the folded versus unfolded conformations detected. The absolute fraction of HMM molecules in the folded/unfolded states did vary from prep to prep, which we believe is due to variations in surface interactions with the EM grid from one experiment to the next. However, the ratio of folded WT/folded E525K was similar in each prep which we feel is the best comparison to make. We found a consistent 4-fold increase in the number of folded molecules in the mutant compared to the WT 15HPZ.GFP (Figure 6 and Table 5).</p><disp-quote content-type="editor-comment"><p>7. This statement: &quot;The clinical significance of this study is that DCM mutations can stabilize the auto-inhibited state of myosin, providing a mechanistic basis for the reduced muscle force and power observed in DCM patients&quot; seems to be an over-stretch from the results of a single mutation. The discussion has a more balanced view of this, stating that many DCM mutations affect other processes and DCM literature is less certain about the reduced activity argument.</p></disp-quote><p>We agree and thank the reviewer for pointing this out. We now state that the manuscript demonstrates that the stabilization of the SRX state is possible in DCM, while studying more mutations is crucial to reveal if this is a common mechanism in DCM (see page 7).</p><disp-quote content-type="editor-comment"><p>8. Last section before the summary and future directions: Surely the fact that nearly 100% of HMM forms SRX at 20 mM KCl should suggest that the signal there represents a fully IHM molecule if the hypothesis is correct. The use of mava would also help here, mava is known to both slow down the ATPase and also allow the formation of IHM. There are conditions, where mava will push nearly everything into the SRX, if you don't see further formation of the FRET sensed IHM then that would suggest this isn't a great IHM sensor. Following the work of Anderson would really help here. They saw approx. 50% SRX without mava that went up to 100% at 25 mM Kac.</p></disp-quote><p>We thank the reviewer for this exciting suggestion. We also thought of the mavacamten experiment, but we ultimately decided this would be best performed in a new study that can fully examine the impact of this drug on 15HP HMM in varying ionic strength conditions. In addition, to thoroughly study the impact of mavacamten we would need to examine the FRET as a function of Cy3ATP concentration at low and high salt in several preparations. In addition, if the drug alters Cy3ATP binding the FRET biosensor would be greatly impacted.</p><disp-quote content-type="editor-comment"><p>Reviewer 2 (Recommendations for the authors):</p><p>1. The author's claim that E525K myosin has a lower kcat value is based on ATPase data from 15-hep constructs which have unusually low activity and extremely high KATPase values (higher than the highest actin concentration used to generate these curves for WT protein). These not only raise doubts about the quality of the protein but will also result in erroneous extrapolated values. The authors should ideally use the S1 constructs to compare kcat values, they already have the viruses for those proteins. The authors should also provide gel images of the purified 15 hep proteins showing the three polypeptide chains.</p></disp-quote><p>The S1 experiments have been added to the manuscript as described above (see Figure 2B and Table 1). The gel in supplemental data shows the comparison of the S1 and 15HPZ constructs (see Figure 2—figure supplement 1).</p><disp-quote content-type="editor-comment"><p>2. It is not clear, and the authors do not discuss, what the fast and slow phases in the Cy3ATP-binding experiments correspond to. WT and E525K proteins have dramatically different proportions (65% vs. 25% of Afast respectively) of the two phases at low salt- a condition where they have similar SRX (STO assays) and IHM (FRET efficiency) proportions. What is the salt dependence of the rates and proportions of these two phases for WT and E525K proteins? It may help the authors to speculate about the origin of these two phases. It appears from panel 4B that these rates are different for E525K at low vs. high salt, but the authors don't comment on that.</p></disp-quote><p>We have added more details to the Cy3ATP binding FRET results and now include a kinetic model to interpret our FRET transients (see pages 5, 9, Figure 4—figure supplements 3&amp;4). See description above.</p><disp-quote content-type="editor-comment"><p>3. The authors should discuss the limitation in the revised manuscript that the R0 value of the FRET pair used here doesn't allow precise measurement of the distances being probed here to be made and refrain from converting FRET efficiency values to distances.</p></disp-quote><p>We now point out the limitations of the FRET based on the R<sub>0</sub> and efficiencies measured (see pages 6 and 10).</p><disp-quote content-type="editor-comment"><p>4. While it is great that the FRET efficiency values calculated from TR-FRET analysis agree well with the values obtained from Cy3ATP binding experiments at low and high salt, it is not ideal to generate a salt-dependence of the FRET efficiency from TR-FRET experiments from just two data-points as shown in Figure 5D. It may be better to present that data as a comparison within 5A itself without drawing a line through them.</p></disp-quote><p>We have removed the line in the TR-FRET graph (Figure 5D).</p><p>[Editors' note: further revisions were suggested prior to acceptance, as described below.]</p><disp-quote content-type="editor-comment"><p>Both the original reviewers and the reviewing editor have read your rebuttal statement and the revised manuscript. All agree that it is much improved although there are still a few points that they would like you to consider. The main concern deals with the idea of 2 different apo-state 15HPZ populations ('open' and 'alt') that differ with respect to their ATP binding affinity. There are some cases in the myosin literature where two exponential nucleotide binding transients have been detected for various myosins, and often the idea of a slow equilibrium between a competent and an incompetent conformation of the myosins has been proposed as opposed to two static populations with inherently different binding rates (See Geeves et al. JBC 275:21624, 2000 for example). Have you considered this? The other concern is that ATP binding to apo-β-cardiac HMM has been reported in the literature to be fit to a single exponential using different experimental set-ups/detection methods:</p><p>a. Bovine cardiac HMM: Rohde et al. 2015, (doi: 10.1073/pnas.1514859112)</p><p>(TR)2 FRET, donor fluorophore is on the RLC, acceptor fluorophore Cy3-ATP</p><p>These authors report that &quot;Cy3-ATP binding to labeled HMM induces a single-exponential time-dependent change in the total fluorescence of the Alexa Fluor donor, consistent with Cy3-ATP binding and formation of a high-FRET state.&quot; (Here the high FRET state is the pre-power stroke state.) Performed under low salt conditions.</p><p>b. Porcine cardiac HMM: Liu et al. (https://doi.org/10.1021/bi5015166)</p><p>Monitored intrinsic tryptophan fluorescence of porcine ventricular HMM at 25 mM KCl upon binding of ATP- data was fitted to a single exponential.</p><p>We realize your readout is different (at least in terms of the position of the donor fluorophore compared with Rohde), and that they are using human protein, but it still seems unlikely that these published studies would see no evidence of two populations under experimental conditions (WT, 20mM KCl) where you see Afast/Aslow of 65%/35%. Also, you are hypothesizing that the population with the decreased binding affinity may represent the IHM state, but then wouldn't you expect to have a smaller Afast for the E525K mutant at 150 mM KCl than WT given your other data?</p></disp-quote><p>The Afast was the dominant signal at 150 mM KCl for WT (0.81) and E525K (0.89). We hypothesize that both WT and E525K are mostly fully open in the Apo state at high salt. Upon ATP binding WT does not favorably transition into the IHM while E525K is still capable of making this transition (see revised section of the Results – page 5-6). Also, we revised the following sentence in the Discussion to clarify this point “We also found that high salt shifts the equilibrium toward the Open conformation in the absence of nucleotide for both WT and E525K, while only the mutant can transition efficiently into the IHM upon ATP binding”. Also, in the discussion we removed the reference to the suggestion that the alternate or incompetent state could be the IHM (see Discussion – page 9).</p><disp-quote content-type="editor-comment"><p>Given these literature results, we think it is reasonable to ask that you examine the binding of Cy3ATP to the myosin constructs directly to complement the FRET experiments. Based on your new model you would expect to see a bi-exponential rate process.</p></disp-quote><p>We measured the Cy3ATP binding as suggested by the reviewers. We found that the fluorescence transients were best fit to a three-exponential function, with two phases that are dependent on Cy3ATP concentration and a third phase that is independent. The third nucleotide-independent slow phase could be an isomerization of the Cy3 fluorophore in the active site. The two different Cy3ATP isoforms have been shown to have distinct fluorescence signatures, which can complicate interpretations of the fluorescence transients of the mixed isomer (Oiwa et al. 2003, Biophys J. 84: 634-642). Since we are monitoring FRET by donor quenching (GFP) the slow phases in the Cy3 fluorescence does not contribute to the FRET signal. Overall, we do observe two rate constants that are linearly dependent on Cy3ATP concentration as we do in the FRET studies.</p><p>The direct binding results are in agreement with our model that suggests there are two static states with different ATP binding kinetics. However, after looking more closely at the Geeves model, we conclude that the direct binding data does not rule out the possibility that there are two states in the absence of nucleotide that are in equilibrium, one that is competent to bind nucleotide and another incompetent. At this range of Cy3ATP concentrations (0.25-2.5 µM) the Geeves model would likely observe two rates that are linearly dependent on Cy3ATP concentration . Therefore, we are in favor of not including the direct Cy3ATP binding measurements because they do not provide additional evidence about the kinetic mechanism. Also, the results are a distraction from the main theme of the paper which is focused on the correlation between the SRX and IHM states and the impact of the E525K mutation. In order to explain the direct binding results it would require significant space and an additional supplementary Figure. Also, there is the issue of the 3rd exponential that is not defined.</p><p>Therefore, we have revised the paragraph in the Results (page 5-6) and in the Discussion (see page 9) to discuss the other possible kinetic mechanism (competent vs incompetent states in equilibrium). We include diagrams of both models in the supplemental data for clarity (see Figure 4—figure supplement 3).</p></body></sub-article></article>